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ABSTRACT 
Porcine reproductive and respiratory syndrome (PRRS), caused by the PRRS virus (PRRSV), 
is a disease of great economic importance for the swine industry worldwide. PRRSV is a 
member of the family Arteriviridae in the order Nidovirales. PRRSV is an enveloped positive 
single-stranded RNA virus, which encodes an approximately 4,000-aminoacid large replicase 
polyprotein ( open reading frame [ORF] 1 a and 1 b) and six structural proteins of 130 to 
265 amino acids (ORFs 2 to 7). Three of these structural proteins have been identified as 
envelope (25 kDa), matrix (19 kDa), and nucleocapsid (15 kDa) proteins, i.e. GP5, M, and N 
proteins, respectively. PRRSV infection poses a challenge to current serodiagnostic and 
vaccination strategies. A better understanding of the mechanisms that regulate immunity to 
this virus will aid in the development of more effective vaccines, as well as serodiagnostic 
assays. 
The idiotype (Id) network theory of immune regulation offered by Jerne (1974), proposing 
that the immune response to a given antigen can be regulated by a series of Id and its 
serological counterpart, an anti-idiotypic antibody (anti-Id or Ab2), has been found useful for 
the production of diagnostic reagents and vaccines. Upon immunization with an idiotypic 
antibody (Abl), the corresponding anti-Ids are elicited and can be serologically classified 
into four categories (Ab2a, Ab2~, Ab2y and Ab2c). Ab2~, an internal image anti-Id Ab2, 
recognizes an Id within the antigen-combining site and bears a structural resemblance to the 
original antigen. The concept of internal image stems from the possibility of raising Ab3 
antibodies that would recognize the original Ag. If one takes into account both the specificity 
and the idiotypic characteristics of Ab 1 molecules, four discrete types of Ab3 molecules may 
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be anticipated: Id-Af, Id+ Ag-, Id-Ag+ and Id+ Ag+, the later being very similar to Ahl and 
termed Ab l '. We have previously suggested the possible role of auto-anti-idiotypic 
antibodies (AAb2) in immunity to PRRSV infection and characterized pig AAb2 specific for 
PRRSV glycoprotein (GP5) as an internal image anti-Id (Ab2~). To further confirm the role 
ofld-anti-Id network in PRRS infection, two studies were performed in a mouse model. In 
the first study, a monoclonal anti-idiotypic antibody (anti-Id), designated as M8G, was 
generated against a monoclonal antibody (MAb 25C) specific for PRRSV glycoprotein 
(GP5). Observations that (i) the anti-Id inhibited the binding of MAb 25C to PRRSV antigen 
and (ii) the Id-anti-Id interaction could be inhibited by PRRSV antigen indicated that the Id 
was located within or near the antigen combining site. The anti-anti-Id antibodies (Ab3) 
induced with anti-Id MAb2, competed with MAbl binding to PRRSV antigen. Furthermore, 
the binding of anti-anti-Id to MAb2 was inhibited with PRRSV antigen, indicating that anti-
anti-Id mimics the structure of the epitope in GP5 which was recognized with Ab 1. These 
serologic findings suggest that anti-Id MAb2 (M8G) carries the internal image of the antigen. 
In the second study, BALB/c mice were immunized with AAb2 and the immune sera (Ab3) 
were tested for the presence of anti-GP5 antibodies and the expression of the Id of Ab 1 
specific for GP5 of PRRSV. Mice immunized with AAb2 were able to produce Ab 1-like 
antibody (Id+ Ag+) responses, i.e., they recognized the same or a similar epitope as Ab 1 and 
possessed the Ab 1 Id, without subsequent exposure to the original antigen. This was 
demonstrated by the following results (i) inhibition of the binding of mouse immune serum to 
AAb2 by PRRSV antigen, (ii) inhibition of binding of mice immune serum to PRRSV 
antigen by pig antisera, (iii) inhibition of AAb2 the binding to MAb 1-25C by Ab3, and (iv) 
inhibition of binding of mouse immune serum to AAb2 by pig antisera. We conclude that pig 
vm 
auto-anti-Id serologically mimics an Ab I-defined GP5 epitope sufficiently to function as a 
surrogate antigen for inducing anti-PRRS virus GP5 responses. 
These results indicate that Id-anti-Id network may be operational in modulating the immune 




This thesis consists of four chapters. Chapter 1 is a general introduction and review of the 
literature on porcine reproductive and respiratory syndrome (PRRS) and idiotypes and anti-
idiotypic antibodies. Chapter 2 and 3 consist of two papers. The first paper, "Monoclonal 
anti-idiotypic antibody specific for GP5 antigen of porcine reproductive and respiratory 
syndrome virus elicits specific immune response in mice" is to be submitted for publication 
in Viral Immunology. The second paper, "Swine auto-anti-idiotypic antibody specific for 
antibodies against GP5 antigen of porcine reproductive and respiratory syndrome virus elicits 
anti-GP5 antibody response in mice" will be submitted to the Journal oflmmunology. The 
last chapter contains the general conclusions of the research studies. References for the 
general introduction and the literature review are in alphabetical order and follow the 
literature review. References for each paper follow the discussion section of each paper while 
the general discussion and conclusion references follow that section. 
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Review of Literature 
Part I: Porcine Reproductive and Respiratory Syndrome 
History of PRRS 
Porcine reproductive and respiratory syndrome (PRRS) was first described in the United 
States in 1987 as a new viral disease of swine (Hill, 1990) and appeared in Europe in 1990 
(Terpstra et al., 1991). The syndrome was initially called mystery swine disease (MSD) 
(Wensvoort et al., 1991) in the United States since no known swine pathogens could be 
implicated. A number of titles have been used to describe this disease syndrome: swine 
infertility and respiratory syndrome (SIRS) (Benfield et al., 1992; Collins et al., 1992; 
Morrison et al., 1992; Yoon et al., 1992), porcine epidemic abortions and respiratory 
syndrome (PEARS) (Pol et al., 1991; Terpstra et al., 1991), blue-eared pig disease (White, 
1991) as well as others. Since the First International Symposium on SIRS/PRRS (1992), 
PRRS has been the internationally recognized name applied to the syndrome (Meredith, 
1993). 
Porcine reproductive and respiratory syndrome virus (PRRSV) 
Porcine reproductive and respiratory syndrome virus (PRRSV) is a recently emerged 
pathogen of domesticated swine. PRRSV is a small, enveloped, positive sense single-
stranded RNA virus that causes reproductive failure in breeding swine and respiratory 
problems in young pigs. PRRSV is a member of the family Arteriviridae in the order 
Nidovirales (Cavanagh, 1997). The arterivirus family consists of PRRSV, lactate 
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dehydrogenase-elevating virus (LDV), equine arteritis virus (EA V), and simian hemorrhagic 
fever virus (SHFV) (Plagemann, 1992). The 5'-capped (Sagripanti et al., 1986) and 3'-
polyadenylated (Brinton et al., 1986; Sagripanti, 1985; van Berlo et al., 1982) RNA is 
polycistronic, containing (5' to 3') two large replicase open reading frames (ORFs), la and 
lb, and several smaller ORFs (Conzelmann et al., 1993; Kuo et al., 1992; Murtaugh et al., 
1995; Smith et al., 1997). In the infected cell, arteriviruses produce a nested set of six to eight 
major coterminal subgenomic mRNAs (sgmRNAs) each thought to express only the relevant 
5'-terminal ORF. These sgmRNAs have a leader sequence derived from the 5' end of the 
genome that is joined at specific leader-body junction sites located downstream by an unclear 
discontinuous transcription mechanism (Lai, 1995). The sgmRNAs of PRRSV encode four 
glycoproteins (GP2 to 5, encoded by sgmRNAs 2 to 5), an unglycosylated membrane protein 
(M, encoded by sgmRNA 6), and a nucleocapsid protein (N, encoded by sgmRNA 7) 
(Bautista et al., 1996; Mardassi et al., 1996; Meng et al., 1994; Meulenberg et al., 1993; 
Mounir et al., 1995; Nelson et al. 1995). The European prototype strain of PRRSV, Lelystad 
Virus (LV), contains all six of these proteins in the viral genom (Meulenberg et al., 1995; 
Meulenberg et al., 1996; van Nieuwstadt et al., 1996), but only the proteins encoded by ORFs 
5 to 7 have conclusively been demonstrated to be in the virion of North American isolates 
(Bautista et al., 1996; Nelson et al., 1995; Pirzadeh and Dea, 1997). Nucleotide and amino 
acid sequence comparisons of the 3'-terminal ORFs 2 to 7 have shown that there are 
significant differences between PRRSV strains native to Europe and those found in North 
America (Kapur et al., 1996; Murtaugh et al., 1995). Therefore, although these two PRRSV 
strains cause similar diseases (Benfield et al., 1992; Wensvoort et al., 1991), they are 
genotypically different in the genes encoding structural proteins. 
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Clinical Manifestations 
Direct contact is the most prominent route of exposure to PRRSV. Persistence of virus in the 
respiratory tract and lymphoid tissues, predominantly tonsil, may occur for up to 157 days 
postinfection (Wills et al., 1997). Production losses and clinical signs will vary considerably 
between farms, depending on the strain of virus (Halbur et al., 1996), management practices 
(Wensvoort, 1993), age of the pig and the herd immune status (Keffaber, 1989; Wensvoort, 
1993). The wide range of variation in the severity of PRRSV infection which is commonly 
observed in both breeding animals and in young pigs may be influenced by coinfection with 
other swine pathogens such as Salmonella choleraesuis, Streptococcus suis, Haemophilus 
parasuis, Actinobacillus pleuropneumoniae, swine influenza virus, porcine respiratory 
coronavirus, pseudorabies virus, or mycoplasmas (Galaina et al., 1994; Thacker et al., 1999). 
Variation in severity may also be due to strain differences among PRRSV (Epperson and 
Holler, 1997; Halbur and Bush, 1997; Hurd et al., 1998; Joo et al., 1998a; Mengeling et al., 
1997; Rossow, 1997; Zimmerman et al., 1997). Low-virulence strains can cause subclinical 
epidemic or endemic infections of herds (Morrison et al., 1992), whereas highly virulent 
strains can cause severe clinical illness. Disease in a naive herd exposed to a virulent strain 
can be devastating. Clinical signs may include anorexia, fever, and lethargy in sows or gilts 
for one to seven days. Cyanotic (blue) ears, vulva, tails, abdomens, and snouts are most often 
seen with infection caused by European strains. Reproductive failure is characterized by late-
term abortions, increased numbers of stillborn fetuses, and/or premature weak pigs. Infection 
during mid-gestation may be followed by abortions, mummified fetuses, early embryonic 
death, and infertility. In some herds, there is a 1-4% mortality in acutely ill sows (Loula, 
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1991) that is sometimes associated with lesions of pulmonary edema or cystitis/nephritis 
(Hopper et al., 1992). Acute phases of disease typically last two to three months after which 
reproductive parameters often return to normal. A persistent reproductive form exhibits 
decreases in the farrowing rate and irregular returns to estrus. The enzootically infected 
breeding herd may appear normal on clinical evaluation. Cycles of high conception failure 
(15-20 percent), stillbirths (10-15 percent), or preweaning mortality (15-20 percent) are 
common. Chronic PRRS problems are typical in seropositive herds which add seronegative, 
susceptible animals without proper isolation and acclimatization. 
Piglets can be infected in utero and be born weak. This is often associated with premature 
farrowing. Infected litters are weak, unthrifty, or splay-legged. Signs in congenitally infected 
pigs may manifest as muscle tremors, eyelid edema, conjunctivitis and/or fever. Pigs may 
display respiratory dyspnea ("thumping"). Increasing incidence of bruising and hemorrhaging 
during processing has been reported. Preweaning mortality has been reported to be as high as 
60 percent (Benfield et al., 1999). Clinical signs in 3 to 10 week old pigs are quite variable. 
Many seropositive herds have no clinical signs of PRRS in growing pigs, particularly when 
weaned early. Most consistent clinical signs observed are associated with respiratory disease 
or ill-thrift. Boars may show anorexia, lethargy, respiratory clinical signs, and also lack 
libido and have variable reduction in semen quality (Feitsma et al., 1992). 
The clinical signs of endemic PRRSV infection in herds are most often obvious in weaned 
pigs in the nurseries or early in the finishing barns when a limited outbreak occurs in a 
susceptible population of pigs (Stevenson et al., 1993 ). Clinical signs in the breeding herd in 
endemically infected herds are usually limited to susceptible gilts or replacement boars that 
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are exposed to PRRSV after introduction into the herd (Dee and Joo, 1994b; Dee et al., 
1996). 
Immunity to PRRS 
Exposure of pigs to PRRSV induces immunity that may protect against reexposure to the 
same virus. However, pigs exposed to PRRSV also demonstrate prolonged viremia and 
persistent infection, they may continue to shed virus, they can become reinfected, and they 
may suffer a repeat episode of the disease. These observations indicate the existence of a 
complex immunological interaction between PRRSV and pigs that involves both induction 
and subversion of host defenses. 
Innate response to PRRSV infection 
Immunity to PRRSV begins with an innate antiviral response in the cytoplasm of an infected 
macrophage. Initial resistance to PRRSV is dependent on antiviral defenses of the infected 
cell and of the innate immune system in the week or more prior to the development of 
adaptive immunity. In an infected pig, the first sign of danger occurs in the cytoplasm of an 
infected macrophage. In viral infections, the presence of double-stranded RNA triggers a 
variety of antiviral functions, of which the induction of the type I interferons, interferon a 
and ~ (IFN a/~), is a hallmark of cellular antiviral defense (Pfeffer et al., 1998; Tizard, 1995; 
Vicek and Sen, 1996). Although PRRSV has positive-sense, single-stranded RNA molecules, 
and PRRSV mRNA appears to have a high degree of double-stranded structure, there is no 
evidence of accelerated RNA degradation or reduced levels of protein synthesis in PRRSV-
infected macrophages. This indirect evidence for a lack of intracellular antiviral activity is 
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consistent with observations that PRRSV infection does not elicit type 1 interferon 
expression in vitro or in vivo (Albina et al., 1998a; Buddaert et al., 1998; van Reeth et al., 
1999). Absence of IFNa production is dependent on replication by PRRSV. The down-
regulation of IFNa production facilitates PRRSV replication since elevation of type I 
interferons by in vivo stimulation or exogenous administration substantially reduces viral 
growth and enhances humoral immune responses (Albina et al., 1998a; Le Bon et al., 2001). 
In addition to IFNa production, inflammatory cytokine expression also is important in the 
initial response to a variety of viral respiratory infections (van Reeth and Nauwynck, 2000). 
PRRSV infection failed to elicit any significant cytokine expression (Thanawongnuwech et 
al., 2001; van Reeth et al., 1999). TNF-a expression was suppressed or declined markedly 
after PRRSV infection (Chiou et al., 2000; Lopez-Fuertes et al., 2000). In virus infection, 
TNF-a and IL-1 ~ are important activators of the nuclear transcription factor, NF-KB 
(Christman et al., 1998; Christman et al., 2000; DiDonato et al., 1997; Regnier et al., 1997). 
NF-KB plays a central role in the innate response to infection by regulating the transcription 
of more than 100 genes, including inflammatory and immunoregulatory cytokines, antigen 
receptors, adhesion molecules, inhibitors of apoptosis, acute phase proteins, and innate 
effector molecules (Schmid and Adler, 2000). It has been speculated that the mild or 
subclinical respiratory involvement in PRRSV infection may be due to the lack of activation 
of NF-KB. Moreover, the lack of an acute inflammatory response and weak innate antiviral 
activity may also result in incomplete stimulation of antigen-specific immune responses, and 
allow for the establishment of persistent infection (Murtaugh et al., 2002). The experimental 
results and observations to date suggest that the initial, innate immune response to PRRSV is 
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weak. In contrast to many host-virus interactions, the IFNa response at the site of infection is 
nil, the production of inflammatory cytokines is minimal and delayed, and the recruitment 
and activation ofNK cells is unremarkable. The lack of an IFNa response is important, 
because IFNa -mediated events inhibit PRRSV replication in vitro (Albina et al., 1998a; 
Buddaert et al., 1998) and because elevation ofIFNa in vivo by preinfection with PRCV 
substantially attenuates subsequent PRRSV replication (Buddaert et al., 1998). Moreover, a 
weak innate immune response to PRRSV is consistent with a suboptimal stimulation of 
antigen-specific humoral and cell-mediated immunity. Influenza virus elicits potent 
inflammatory cytokine and interferon responses in the lung, and is rapidly cleared within 1 
week of infection (Brown et al., 1993), whereas PRRSV viremia has been observed for 6 to 7 
weeks after infection (Suarez, 2000), and the virus can be reisolated months after initial 
infection (Albina et al., 1994; Christianson et al., 1992; Labarque et al., 2000; Rossow, 
1998). 
Humoral immune response to PRRSV 
The antibody response to PRRSV has been studied extensively. Anti-PRRSV IgM antibodies 
appear in serum by 5 to 7 days postinoculation (Pl) and then decline rapidly to undetectable 
levels after 2 to 3 weeks (Joo et al., 1997; Loemba et al., 1996; Park et al., 1995; Yoon et al., 
1995). Anti-PRRSV lgG antibodies are first detected 7 to 10 days PI (Labarque et al., 2000; 
Loemba et al., 1996; Yoon et al., 1995), peak at 2 to 4 weeks PI, remain constant for a period 
of months, and then decline to low levels by 300 days PI (Nelson et al., 1994; Nielsen and 
B0tner, 1997). Anti-PRRSV antibodies may persist in blood for the lifetime of commercial 
pigs. A group of 11 pigs infected experimentally remained seropositive for 600 days and 
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were protected completely against challenge with the homologous strain of virus (Lager et 
al., 1997). 
Immunoglobulins of the IgG 1 subclass appear at day 9 PI, while IgG2 subclass antibodies are 
first detected at day 14 PI, but at a lower level (Labarque et al., 2000). Anti-PRRSV IgA can 
be detected in serum at 14 days PI, reaches a maximum at 25 days PI, and remains detectable 
until 35 days PI. The kinetics of anti-PRRSV antibody isotypes in bronchoalveolar lavage 
(BAL) fluid are similar to those in serum, indicating these antibodies extravasate from the 
vasculature (Labarque et al., 2000). The antibodies in BAL may contribute to the clearance 
of PRRSV from the lung, but are unable to completely eliminate the virus (Labarque et al., 
2000). Serum neutralizing (SN) antibodies are reported to appear at about 3 weeks post 
infection (Albina et al., 1998b; Eichhorn and Frost et al., 1997; Loemba et al., 1996), 
although SN antibodies have been reported at 9 days PI (Yoon et al., 1994). Slow-reacting 
complement-requiring neutralizing antibodies have been demonstrated as early as 8 days PI 
(Jusa et al., 1996; Takikawa et al., 1997). SN antibodies are maintained for long periods, but 
at low levels (Albina et al., 1998b; Labarque et al., 2000; Loemba et al., 1996; Yoon et al., 
1995). Substantial variation has been noted in the SN antibody responses of individual pigs, 
in both the kinetics of appearance and in titer values (Loemba et al., 1996; Yoon et al., 1995). 
Nelson et al. (1994) also reported animals that failed to seroconvert in the SN test. Anti-
PRRSV immunoglobulins in serum after PRRSV infection are directed primarily against 
PRRSV N protein ( encoded by ORF 7) and M protein ( encoded by ORF 6) (Dea et al., 2000). 
Antibodies against N protein can be detected within 7 days of infection, whereas antibodies 
against M protein appear by the end of the second week PI (Loemba et al., 1996; Nelson et 
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al., 1994; Yoon et al., 1995). Anti-GP5 ( encoded by ORF 5) antibodies may also appear by 
day 7 PI (Dea et al., 2000; Loemba et al., 1996; Nelson et al., 1994; Yoon et al., 1995). 
Neutralizing antibodies to PRRSV have been reported with specificities against GP5, GP4, 
and M (Halbur et al., 1997; Meulenberg et al., 1997; Ostrowski et al., 2002; Pirzadeh and 
Dea, 1997; Pirzadeh and Dea, 1998; Weiland et al., 1999; Yang et al., 2000). Murine 
monoclonal antibodies against GP5 are more effective in virus neutralization than 
monoclonal antibodies to GP4 (Weiland et al., 1999). The immune response to individual 
structural proteins in serum of pigs recovered from PRRSV infection has been examined by 
serological reactivity to GP3, GP4, GP5, and N expressed as recombinant fusion proteins 
with glutathione-S-transferase (GST). SN titers were significantly correlated with anti-GP5 
titers but not with anti-GP4 titers (Gonin et al., 1999; Ostrowski et al., 2002; Pirzadeh and 
Dea, 1997; Weiland et al., 1999). Antibodies against GP3 also may have a role in protection 
against PRRSV infection, though the data are less direct (Dea et al., 2000; Plana Duran et al., 
1997). 
Antibody responses are elicited to nonstructural proteins (nsp) of the replicase complex, 
particularly the nsp 2 polypeptide encoding a putative cysteine protease (Meulenberg et al., 
1993; Oleksiewicz et al., 2001b). The antibodies recognize linear epitopes in nsp 2 and 
appear within 1 to 4 weeks of infection (Oleksiewicz et al., 2001b). These antibodies are 
detected in boar semen and their presence is correlated with the duration of PRRSV excretion 
in semen (Oleksiewicz et al., 2001a). Humoral immune responses have also been evaluated 
in response to DNA vaccination with plasmids containing expression cassettes for various 
structural proteins. Antibodies against GP5 were detected 15 days after ORF 5 DNA 
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vaccination by indirect immunofluorescence (IF A) and ELISA, and neutralizing antibodies 
were demonstrated 2 to 3 weeks after the second booster injection, 8 to 9 weeks after the first 
inoculation (Pirzadeh and Dea, 1998). After PRRSV challenge, the neutralizing titers rose to 
approximately 128. In another DNA vaccination study, ELISA antibodies were detected 
against N after three immunizations and against M after four immunizations (Kwang et al., 
1999). 
Colostral antibody responses are closely correlated with serum antibody responses. For 
example, sera-positive sows were colostrum-positive, and all colostrum-negative sows also 
were sera-negative (Eichhorn and Frost, 1997). Because the concentration of IgG in 
colostrum exceeds that found in serum (Pastoret et al., 1998), sows may be colostrum-
positive but sera-negative (Eichhorn and Frost, 1997). Colostral IgG is absorbed by suckling 
newborn piglets within 24 to 48 h of birth via the apical tubulovesicular membrane system 
(ATVM) into serum (Pastoret et al., 1998). These maternal antibodies are reported to persist 
in piglets up to 6 to 8 weeks of age (Chung et al., 1997; Houben et al., 1995). 
Attenuated, live vaccines have been widely used in swine farming and have proven effective 
in reducing disease severity, duration of viremia, virus shedding, and the frequency of 
PRRSV infection (Christopher-Hennings et al., 1997; Dee et al., 1998; Mavromatis et al., 
1999; Mengeling et al., 1999; Nielsen et al., 1997; van Woensel et al., 1998). The humoral 
immune response is presumed to play an important role in resistance to reinfection and in 
prevention or reduction of viral spread from animal to animal, since neutralizing antibodies 
have the potential to clear free virus from the circulation (Albina et al., 1994; Molitor et al., 
1997; Ostrowski et al., 2002; Yoon et al., 1995). Reproductive failure due to PRRSV 
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infection also has been prevented by administration of serum containing a high titer of SN 
antibody (Osorio et al., 2002). 
Despite these results, the role of neutralizing antibodies in prevention of disease and in 
protection of pigs from infection under field conditions is not clear. Since viremia may occur 
in the presence of SN antibodies (Christianson et al., 1992; Dee et al., 1998; Rossow et al., 
1994; Wills et al., 1997), the level of neutralizing antibodies normally generated against 
PRRSV may not be sufficient to control the replication of the virus. Selection of 
neutralization escape mutants has been proposed as one mechanism to account for inefficient 
neutralization (Bautista and Molitor, 1997; Rowland et al., 1999), but neutralization escape 
mutants or genetic variation in the neutralization-sensitive ectodomain regions of GP5 have 
not been observed in experimental or field settings (Chang et al., 2002; Le Gall et al., 1997; 
Madsen et al., 1998; Rowland et al., 1999; Storgaard et al., 1999). Moreover, all monoclonal 
antibodies bind both glycosylated and nonglycosylated forms of GP5, indicating that 
glycosylation is not associated with neutralizing epitopes of the protein (Dea et al., 2000; 
Pirzadeh and Dea, 1997; Pirzadeh and Dea, 1998; Weiland et al., 1999; Zhang et al., 1999). 
The phenomenon of antibody-dependent enhancement (ADE) also might reduce the 
effectiveness of a neutralizing antibody response (Kurane et al., 1991). Low titers of 
neutralizing antibodies may increase the association of viral particles with permissive 
macrophages through binding of virus-antibody complexes to the Fe receptor, and thus 
facilitate viral binding and uptake through the macrophage PRRSV binding protein (Choi et 
al., 1992; Christianson et al., 1993; Yoon et al., 1996; Yoon et al., 1997). Infection of 
alveolar macrophages by PRRSV is significantly enhanced in vitro in the presence of diluted 
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anti-PRRSV antisera (Yoon et al., 1996), and the mean level and duration ofviremia are 
greater in pigs injected with SN antibodies prior to virus challenge than in pigs injected with 
normal IgG (Christianson et al., 1993; Yoon et al., 1996). The prolonged duration ofviremia 
and virus isolation from the tissues in piglets with low maternal antibodies also suggests 
ADE of PRRS (Shibata et al., 1998). Alternatively, slow development of an effective 
neutralizing antibody response might be due to the presence of immunodominant 
nonneutralizing epitopes on GP5 that act as a decoy to delay the induction of antibody 
production directed against neutralizing epitopes of the protein (Ostrowski et al., 2002). 
However, the appearance of antibodies in serum to an immunodominant, highly conserved, 
nonneutralizing GP5 epitope is itself slow and incomplete, with only 50% of animals 
seroconverting 56 days after PRRS virus infection (Oleksiewicz et al., 2002; Rodriguez et al., 
2001 ). Whether induction of antibody production to neutralizing epitopes is an inherent 
characteristic of the epitopes themselves or is determined by a decoy process is not known at 
this time. 
Cell-mediated immune response to PRRSV 
PRRSV infection in the lung peaks at approximately day 9 after infection and foci of 
infection decline to near zero by day 20, although virus still may be isolated from lung fluids 
for extended periods (Labarque et al., 2000; Mengeling et al., 1996; Samsom et al., 2000). 
During and subsequent to the decrease in PRRSV titer, lymphocyte numbers may either 
remain low or constant (Labarque et al., 2000) or increase substantially (Samsom et al., 
2000) in the lung. Samson et al. (2000) identified a CD4(-) CD8(+) T cell population that 
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increased in the lung at later times. The lymphocytes were classified as cytotoxic T cells 
based on a cell marker phenotype of CD6(-) CD8( + ). Shimizu et al. (1996) also observed a 
substantial increase in CD8(+) T cells that peaked at 25-35 days after infection. In peripheral 
blood during the first week of PRRSV infection, there is a transient leukopenia and 
lymphopenia in peripheral blood that resolves in 8 to IO days (Christianson et al., 1993; 
Nielsen and B0tner, 1997). The absence of a corresponding increase in lymphocyte numbers 
in the bronchoalveolar fluids at this time indicates that this change is not a direct response to 
the virus (Labarque et al., 2000; Samsom et al., 2000). 
PRRSV-specific T cell responses first appear in peripheral blood at approximately 4 weeks 
after infection (Bautista and Molitor, 1997). An antigen-specific proliferative response was 
observed for 5 weeks, that is, until 9 weeks after infection. The proliferative response was 
inhibited approximately 80% and 90% by anti-CD4 and anti-MHC II antibodies, 
respectively, and by 50% and 75% by anti-CD8 and anti-MHC I, respectively (Bautista and 
Molitor, 1997). Challenge with the homologous virus restimulated a specific proliferative 
response in peripheral blood mononuclear cells, which was detected for 3 weeks (Bautista 
and Molitor, 1997). In vivo specific cell-mediated reactivity to PRRSV antigen was 
confirmed by a delayed type hypersensitivity reaction to inactivated PRRSV (Bautista and 
Molitor, 1997). Lopez Fuertes et al. (1999) also reported PRRSV-specific lymphocyte 
proliferation at 4 weeks PI. In this case, the responsive T cell type also was predominantly 
CD4( +) and was present for a period of 10 weeks after infection. Stimulated cells expressed 
IFNy and IL-2, but not IL-4 or IL-10, suggesting that the CD4(+) T cells possessed a type I 
cytokine expression phenotype characteristic of cell-mediated immune responses to 
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intracellular pathogens (Lopez Fuertes et al., 1999). In vitro restimulation of PBMC with 
PRRSV antigen and IL-2 showed that the responding cells were primarily CD8(+) 
(Zuckermann and Husmann, 1996). T-cell proliferation is induced in response to individually 
purified structural proteins GP5, M, and N (Bautista et al., 1999). Expression of GP2, GP4, 
GP5, M, and N individually in a vaccinia virus system revealed that the nonglycosylated M 
protein was the most potent inducer of proliferation, followed by GP5, GP3, and GP2, 
whereas N was the weakest inducer (Bautista et al., 1999). Host IFNy production is central to 
protective mechanisms in a variety of cytopathic viral infections in murine models (Ramsay 
et al., 1993; Zinkemagel et al., 1996). Thus, it is possible that IFNy also mediates protection 
against viral infections in pigs. Support for this notion exists in the observation that the 
efficacy of pseudorabies virus vaccines is positively correlated with the generation ofvirus-
specific IFNy-producing cells, but not with the generation of neutralizing antibodies 
(Zuckermann et al., 1998; Zuckermann et al., 1999). IFNy mRNA has been detected in the 
lymph nodes, lungs and peripheral blood mononuclear cells of PRRSV-infected pigs (Lopez 
Fuertes et al., 1999; Rowland et al., 2001 ). Moreover, IFNy blocks PRRS virus replication in 
cultured cells (Bautista et al., 1999) apparently by the inhibition of viral RNA synthesis via a 
double-stranded RNA-inducible protein kinase (Rowland et al., 2001). The observation that 
PRRSV persists in lung and lymph nodes despite the presence of neutralizing antibodies in 
serum and bronchoalveolar lavage fluid (Albina et al., 1994; Chung et al., 1997; Labarque et 
al., 2000; Wills et al., 1997; Zimmerman, 1999) argues that cell-mediated immunity is 
necessary for the complete elimination of the virus. Nevertheless, the existence of PRRSV 
persistence also suggests that cell-mediated immunity is not potent and that IFNy production 
is either weak or ineffective. 
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Analyses of the IFNy response to PRRSV infection revealed that the frequency of virus-
specific IFNy-producing lymphocytes in the blood of pigs ranged from approximately 50 to 
100/106 PBMC at 13 weeks after infection with virulent PRRSV or 8 weeks after a live, 
attenuated booster vaccination (Meier et al., 2000). In contrast, greater than 400 virus-
specific IFNy-producing lymphocytes/106 PBMC were detected within 2 weeks after 
secondary immunization with a live, attenuated pseudorabies vaccine (Meier et al., 2000). 
This level of IFNy response was not achieved until 23 weeks after a similar immunization 
protocol with a PRRSV vaccine. Thus, the cell-mediated immune response to PRRSV, as 
measured by the frequency of PRRS virus-specific IFNy secreting cells, is weak. The 
significance of a relatively low IFNy response as it relates to protective immunity is not 
known. In pseudorabies virus, a frequency of>400 antigen-specific IFNy secreting cells/106 
PBMC correlates with effective protection of pigs against the clinical consequences of 
challenge with a virulent form of this virus (Zuckermann et al., 1999). Pigs that have 
recovered from a previous PRRSV infection demonstrate resistance to a secondary challenge 
by the homologous strain at least up to 604 days after the initial infection (Lager et al., 1997). 
After re-challange, there is a high frequency of PRRS virus-specific IFNy secreting cells (450 
± 50/106 PBMC), whereas the humoral immune response is barely detectable (Meier et al., 
2000). The intensity of the IFNy response to either wild type or attenuated PRRSV increases 
gradually over a period of months, while humoral immunity decreases (Meier et al., 2000). 
These contrasting changes in immune response are intriguing, but the mechanisms 
responsible have not been identified. Because IFNy plays a key role in cell-mediated immune 
responses, factors that increase its expression might enhance anti-PRRSV cell-mediated 
responses. IL-12 and IFNa, in particular, are involved in the differentiation of naive T cells 
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into antigen-specific IFNy-secreting cells (Banyer et al. 2000; Cousens et al. 1999; Kadowaki 
et al. 2000; Tough et al. 1999). In pigs, potently immunogenic viruses induce high levels of 
inflammatory cytokine and type 1 interferon expression (van Reeth et al. 1999), whereas 
PRRSV does not stimulate significant amounts of either in the lung (Albina et al. 1998a; 
Buddaert et al., 1998; van Reeth et al. 1999). It is possible that the production of type 1 
interferon or appropriately stimulatory cytokines during the innate immune response are a 
critical element that is missing from the anti-PRRSV response (Murtaugh et al., 2002). Novel 
vaccine approaches against PRRSV have been used for further characterization of cell-
mediated immune responses and for evaluation of protective efficacy. DNA immunization of 
pigs with plasmids encoding PRRSV GP4, GP5, M, or N induced the appearance of 
peripheral blood lymphocytes responsive to PRRSV measurable by antigen-specific 
proliferation or IFN production (Kwang et al., 1999). The responses were observed after two 
immunizations, at least 3 weeks earlier than ELISA or Western blot evidence of an immune 
response was detected (Kwang et al., 1999). GP5-specific lymphocyte proliferation was also 
observed in pigs immunized with plasmid DNA encoding ORF 5 (Kwang et al., 1999). In 
this case, specific neutralizing antibodies also were elicited, and pigs were protected from 
viremia and macroscopic lung lesions induced in unvaccinated pigs by virulent PRRSV 
(Pirzadeh and Dea, 1998). Plana Duran et al. (1997) also reported that immunization with 
GP3 or GP5 protein confers protection against challenge with virulent PRRSV, though 
immunization with GP5 did not protect pigs from challenge in another study (Pirzadeh and 
Dea, 1998). 
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Prevention and Control 
Prevention of PRRS in a naive herd depends on the ability to prevent introduction of infected 
animals. This is a challenge considering the number of routes of transmission possible. 
Primary transmission is via direct contact but aerosol and fomite transmission are possible. 
Pigs can be nonclinical carriers for several months and PRRSV can persist in some animals 
despite high levels of antiviral antibodies; in boars, this is associated with long-term, 
intermittent seminal excretion of the virus (Christopher-Hennings et al., 1995; Gradil et al., 
1996). Therefore, it is critical to routinely isolate and test breeding stock before introducing 
them to a PPRS-negative herd. Replacement stock to be added to naYve herds should be 
obtained from known negative sources that carry out a regular schedule of herd monitoring 
(Benfield et al., 1999). Following the arrival of new stock, all animals should be blood-tested 
14 days following entry into the isolation building. Isolation periods should be at least 30 
days to allow sufficient time to obtain laboratory results prior to animal introduction 
(Benfield et al., 1999). Serological tests cannot discriminate between seropositive animals 
which have cleared PRRSV infection and carrier animals. Since there are multiple strains of 
the PRRSV, serological tests must be correctly selected. Control strategies must be tailored 
to individual farms. Strategies must be based on epidemiology of the virus, facilities 
available, pathogenicity of virus strain involved, and management resources. 
PRRSV infection poses a challenge to current vaccination strategies. Several studies have 
stablished that vaccination against PRRS can result in protective immunity (Gorcyca et al., 
1995; Gorcyca et al., 1996b; Hesse et al., 1996a, b; Mengeling et al., 1996;). Although live 
PRRSV vaccines provide protection against homologous challenge, the genetic diversity of 
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field PRRSV isolates is very high, and vaccine effect against heterologous challenge may be 
limited (van Woensel et al., 1998). Also, live PRRSV vaccines have been observed to revert 
to virulence (B01:ner et al., 1997; Storgaard et al., 1999), and the safer, killed vaccines have 
so far proved less effective (Nielsen et al., 1997). Addressing these problems might involve 
improving the design of antigens for vaccines. For example, PRRSV envelope glycoproteins 
are candidates for use in subunit vaccines (Durand et al., 1997), and the nonstructural ORF 
1 polyprotein could be a possible candidate antigen for the development of serological tests 
to identify carrier animals (Neitzert et al., 1991). Production of full-length recombinant 
proteins to explore such potential applications may be hampered by the presence of 
hydrophobic regions and, for the ORF 1 polyprotein, a very large size and the ability to 
undergo autoproteolytic cleavage. This could be overcome by expression of protein subunits, 
guided by prior knowledge of naturally antigenic regions. However, no knowledge currently 
exists about epitopes in the PRRSV ORF 1 nonstructural polyprotein, and only two epitopes 
have been mapped in the envelope glycoproteins (Meulenberg et al., 1997; Oleksiewicz et 
al., 2000), one of which was mapped using monoclonal antibodies (MAbs) and thus is of 
unknown significance for PRRSV infection in vivo (Meulenberg et al., 1997). 
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Part II: ldiotypes and Anti-idiotypic Antibodies 
History of Anti-idiotypic antibodies 
An antibody is usually defined in terms of the antigen it recognizes. An antibody's specificity 
for a particular antigen is determined by its antigen-binding site, the distinct region of the 
antibody molecule that makes contact with an antigen. This site is found within the variable 
(V) regions of immunoglobulin heavy (VH) and light (VL) chains. 
However, an antibody may also be defined by its idiotopes, or surface markers, associated 
with the unique VH and VL regions of a monospecific population of antibody molecules. 
Idiotopes may be either in the antigen-binding site or on the framework regions of the 
variable domain. There are usually several idiotopes in each V domain, some unique to that 
antibody (private idiotopes), and others shared with some other antibodies (public idiotopes). 
Public idiotopes are thought to be derived from germ-line gene products (Dreesman and 
Kennedy, 1985). The sum of the idiotopes on an antibody's V domain determines its idiotype 
(Id). Idiotypes are useful markers because they enable researchers to follow the appearance 
and persistence of particular antibodies in immune responses and inherited immunoglobulin 
genes (Green and Nisonoff, 1984). Ids are also unique determinants that can stimulate 
production of antiidiotype ( anti-Id) antibodies. 
The possibility that an antibody might be produced against the combining region of another 
antibody was suggested by Ehrlich and Morgenroth (Oudin and Michel, 1963). They 
proposed that autoimmunity to red blood cells was prevented by the formation of an auto 
anti-lysin that combined with and inactivated lytic antibodies to red cells. Their hypothesis 
was actually closely related to the "internal image" concept later elaborated by Niels Jeme 
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(discussed below); because they postulated that the anti-antibody had combining groups or 
"side chains" equivalent to side chains on red cells. The lysin was therefore able to induce the 
secretion of anti-antibodies through interaction with the same side chains that are present on 
red cells. Virtually nothing was known, of course, about the chemical nature of an antibody. 
The first studies to characterize idiotypic determinants on antibody molecules were 
performed by Oudin and Michel, and by Kunkel et al. in 1963 (Kunkel et al., 1963; Oudin 
and Michel, 1963). These studies examined antisera generated against homogeneous 
immunoglobulins (from multiple myelomas and Bence Jones proteins) and revealed the 
antigenic individuality of immunoglobulin molecules. In 1974, Neils Jeme proposed a 
biological significance for idiotypic determinants in his network theory of immune 
regulation. Jeme theorized that an immune response to a given antigen is controlled by a 
series ofld-anti-Id reactions that may either enhance or suppress an immune response (Jeme, 
1974). The antibody made in response to the original antigen itself becomes an antigen and 
elicits the synthesis of a second, anti idiotypic antibody. Thus, a given Id (Ab 1) is under 
control of an anti-Id (Ab2), and the anti-Id may be regulated by another set of antibodies 
referred to as anti-anti-Id (Ab3). According to this original network hypothesis, the Id-anti-Id 
interactions regulate the immune response of a host to a given antigen. Jeme's network theory 
successfully explained the appearance of "anti antibodies" previously noted by many 
laboratories. As a result, new emphasis was placed on self-recognition as an essential 
component of immune regulation. 
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Classes of Anti idiotypic Antibodies 
A heterogeneous population of anti-Id is obtained when syngeneic inbred animals are 
immunized with Id. Anti-Ids can be serologically classified into four categories (Ab2a, 
Ab2B, Ab2y and Ab2£) (Bona and Kohler, 1984; Jerne, 1974; Jerne et al., 1982). The 
parameters used to define each anti-Id focus primarily on whether it binds within the antigen-
binding site or to some other region of the Id (Fig. I). If the relevant antigen or hapten inhibits 
the binding of anti-Id to Id, the target idiotope is believed to be in the antigen-binding site, 
and the anti-Id is referred to as Ab2B. Anti-Ids that are not inhibited by antigen are 
designated Ab2a and presumably bind to sites in the framework region. Ab2y recognizes an 
Id within the antigen-combining site but does not carry the internal image of the original 
antigen. Ab2y may partially block Ag-Abl binding due to steric hindrances or allosteric 
effects. Ab2£ is defined as the antibody that recognizes the Id of Ab 1 and an epitope on the 
antigen (Bona and Kohler, 1984). 
Internal image antibodies 
Ab2B that can displace an antigen from the antigen-binding site of an antibody may "look" 
like the antigen and are referred to as internal image anti-Id. It is therefore important to 
define the criteria for internal imagery. The first criterion is the ability to mimic antigen. An 
Ab2B must be capable of inducing an antibody response of the same specificity as the antigen 
it mimics or to act like a natural ligand for a cellular receptor. This functional criterion also 
suggests that internal images can induce T cell mediated functions via interactions with T cell 
receptors. The second criterion is the ability to function as antigen in a variety of animal 
44 
honnone ·----~ ~~~" V 
. ---




,,, ••••.,..,.'' I 
;, .. •· ~: 
---------······-· 
Ab1 
,. ............. ~ 
✓- Ab2y 
--<,.. 
Figure 1. Interactions of different Ab2 with Ahl (Green and Nisonoff, 1984). 
species or inbred strains. This criterion is a means of distinguishing Ab2B from Ab2a, Ab2 or 
Ab2E. 
Internal imagery of anti-Ids was first reported when anti-Ids raised against antibodies to 
insulin reproduced certain physiological reactions of the hormone itself when bound to 
insulin receptors (Sege and Peterson, 1978). Subsequently, anti-Id mimicry of bacterial, viral, 
parasitic, and tumor antigens proved successful in generating experimental anti-Id vaccines 
(Kennedy and Dreesman, 1986; Langone, 1989). All evidence to date indicates that anti-Id 
mimicry of antigens is due to similarities in three-dimensional structural conformations and, 
in some cases, to regions of DNA-sequence homology between antigen and anti-Id. 
Crystallographic analysis of a lysozyme-Abl Fab complex and an Abl Fab-Ab2 Fab 
complex showed that the anti-Id antibody and the antigen completely overlapped in their 
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binding to the Ab 1 (Bentley et al., 1990). Moreover, it has been shown that the interacting 
molecular surfaces of the two Id-anti-Id Fab fragments greatly resembled the structural 
features of a typical antigen-antibody complex (Ban et al., 1994). Sequence homology 
between anti-Id and antigen has been clearly demonstrated for reovirus type 3 hemagglutinin 
as well (Williams et al., 1989). In fact, the V H and V L complementarity determining region 1 s 
(CDRls) of the anti-Id showed sequence homology with regions of the antigen, suggesting 
that these are the sequences and structures of the external antigen mimicked by the anti-Id. 
Whether an anti-Id can accurately mimic an antigen depends greatly on its chemical nature. 
In the most common antigens such as proteins, peptides, small haptens, and carbohydrates, 
the groups forming the major epitopes are chemically dissimilar and present different 
problems for mimicry by anti-Id (Amzel et al., 1994). Complex antigens, including tumor 
antigens, contain multiple epitopes. The immune recognition which they evoke, therefore, 
contains many idiotopes which are determined not only by the heterogeneity of the epitopes, 
but also by the heterogeneity of the V genes selected among lg and T cell receptor genes in 
the host. These idiotopes are largely defined by the anti-idiotopes which they induce. Thus 
private idiotopes elicit Ab2 responses which are unique for a particular Ab 1, public idiotopes 
elicit Ab2 to a specificity shared by many Ahl, and Ab2 of the internal image type are 
induced against antigen-binding structures on Ab 1 which are complementary to the antigen 
(Augustin et al., 1983; Mosier and Feeney, 1984; Urbain et al., 1982). 
Ab2 immunization can lead to Ab3 elicitation not only through specific V gene network 
interactions but also by virtue of internal-image mimicry (Augustin et al., 1983; Urbain et al., 
1982). That is, when the anti-idiotype represents the conformational mirror image of the 
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antigen, it can substitute for nominal antigen and elicit an Ab I-like response (Nisonoff and 
Lamoyi, 1981). In an embodiment of the invention employing monoclonal anti-idiotypes, the 
appropriate Ab2 should be carefully selected. The experimental verification that any 
particular Ab2 is an internal image type of anti-idiotype hinges on its ability to mimic the 
conformational characteristics which define recognition of the antigen. Internal image anti-
idiotypes compete in vitro with antigen for binding to idiotype-positive Ab 1, and prime in 
vivo for Ab3 which mimic Ab 1 (Nisonoff and Lamoyi, 1981 ). In addition to the inhibition of 
Ab 1 binding to antigen, internal image Ab2 can substitute for antigen in terms of immune 
recognition. For example, Ab2 may stimulate antigen-specific clones in vitro in the absence 
of antigen, or Ab2+ cells may serve as a target for antigen-specific CTL (Ertl et al., 1982). 
The ability of internal image Ab2 to compete with antigen for binding to Ab 1 ( and vice 
versa) is an integral part of their behavior. However, Ab2 which do not function as internal 
images may still compete, due to steric hindrance ( and perhaps other mechanisms as well), so 
anti-idiotypic antibodies which do not have internal image specificity may still display 
internal image-associated properties (Lee et al., 1986; Schick et al., 1987). 
If one takes into account both the specificity and idiotypic characteristics of Ab 1 molecules, 
four discrete types of Ab3 molecules may be anticipated: Id- Ag-, Id+ Ag-, Id- Ag+, Id+ Ag+ 
(Corbet et al., 1988). The latter includes antibodies that resemble Abl by reacting with the 
same antigen: they are designated Ab l' and the Ab2 inducing them is termed the internal 
image of the antigen. Anti-Ids have been used to raise antibodies against various pathogens 
and tumor antigens and have often been discussed as possible vaccines. The relationship 
between Ab 1 and Ab 1' antibodies has been explored in a number of different antigenic 
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systems, and with either monoclonal or polyclonal anti-Id reagents (Bhattacharya-Chatterjee 
et al., 2000). One result obtained consistently is that among Ab3 antibodies are some which 
do indeed closely resemble the Ab 1 in that they possess the same idiotopes, bind to the same 
antigen and derive from similar variable (V) genes. However, while the resemblance between 
Abl' and Abl can be very close, many permutations ofresults have been seen. For example, 
binding of Ab3 to the antigen may not occur even though the same V-gene segments are 
selected, e.g. where the selection by anti-Id is directed towards the V segment rather than D 
and J idiotopes; or the affinity of Ab 1' antibodies for antigen may be lower than that of the 
Ahl, corresponding to differences in the complementarity determining region (CDR), 
particularly H3 sequences; or the Ab3 may bind a similar antigen, yet diverge considerably 
from the Abl in V genes and CDRs. Thus, depending perhaps on the nature of the Ab2 
reagent, an Ab3 population can be more or less heterogeneous and include molecules with a 
range of fidelities to the Ab 1. 
According to Goldbaum et al. (1997), there are two major possibilities for the induction of 
anti-anti-Id (Ab3) that resemble Abl. One is that a suitably selected anti-Id will mimic the 
antigen so closely as to produce the equivalent of an antibody response to the original 
antigen. A second possibility is that the anti-Id is specific for the Id and will thus stimulate 
lymphocytes displaying anti-anti-Id immunoglobulins that should be identical or essentially 
identical to the Ab 1. By immunochemical criteria it is difficult to discriminate between Ab2B 
and Ab2y. To sort out both types of Ab2 a functional demonstration should be observed. 
Since Ab2B express an idiotype that mimics the antigen, it might have the capacity to elicit 
antibodies specific for the antigen in the same or different species. The concept of internal 
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image stems from the possibility of raising Ab3 antibodies that would recognize the original 
Ag (J erne et al., 1982). 
Application of anti-idiotypic Antibodies 
Anti-idiotypic antibodies, and especially those that mimic the antigen or ligand (Ab2B), are 
being explored in the development of new vaccines, the treatment of cancers ( especially T 
and B cell cancers), hormone or ligand mimicry and as immunodiagnostic reagents. 
I. Anti-idiotypic Vaccines 
The network hypothesis offers an elegant concept for developing vaccines that are not based 
on the conventional approach of using nominal antigen. These so-called anti-Id vaccines or 
internal Ag vaccines take advantage of the fact that the repertoire of external or nominal 
antigens is mimicked by Id structures on immunoglobulins and possibly on receptors and 
products of T cells as well. Thus, with this approach, Id-based vaccines do not contain 
nominal Ag or its fragments. The ability of Ab2a and Ab2B to induce the immune responses 
(both antibody and T cell responses) to a given pathogen has been shown in many model 
systems including viruses (Dinca et al., 1993; Francotte and Urbain, 1984; Kennedy and 
Dressman, 1984; Kennedy and Dressman, 1986; Kennedy et al., 1986; Oosterlaken et al., 
1991; Orten et al., 1991; Schick et al., 1987; Zhou et al., 1987; Zhou et al., 1990), bacteria 
(Kaufmann, 1985; McNamara et al., 1984; Su et al., 1992), and parasites (Kresina and Olds, 
1989; Sacks and Sher, 1983; Velge-Roussel et al., 1989). 
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Vaccinating with anti-idiotypic antibodies (Ab2~) (that carry the internal image of the 
antigen) offer a number of advantages over immunizing with conventional vaccines. Anti-
idiotypic antibodies are not infectious yet can generate an immune response against the 
pathogen. In addition, anti-idiotypic antibodies induce a more effective T cell response than 
inactivated viruses do. Also, they are useful when it is difficult or hazardous to obtain large 
quantities of the antigen. It is thought that they diminish the potential of autoimmune 
diseases arising as a result of antibodies that are generated to other epitopes on the antigen or 
other antigens on the viral coat (Dreesman and Kennedy, 1985). They may also prove to be 
beneficial when the epitopes is a carbohydrate, lipid, or DNA (since these epitopes may be 
more difficult to mass produce than an anti-idiotypic antibody protein). This may be useful in 
developing vaccines for parasitic infections (Burdette and Schwartz, 1987; Eichmann and 
Rajewsky, 1975; Kearney, 1989). Rodent anti-idiotypic vaccines for immunization against a 
number of pathogens have been developed. For bacteria, there are anti-idiotypic vaccines 
against Escherichia coli, Streptococcus pneumoniae, and Brucella abortus. Both the 
idiotypic (Abl) and the anti-idiotypic (Ab2) antibody were capable of immunizing mice 
against E. coli (Beauclair and Khansari, 1990; McNamara et al., 1984 ). Rodent anti-idiotypic 
vaccines have been generated against the following viruses: murine leukemia virus, murine 
mammary tumor virus (MMTV), reovirus, poliovirus, rabies virus, hepatitis B virus, and the 
human immunodeficiency virus (HIV) (Burdette and Schwartz, 1987; Kennedy et al., 1986; 
Thanavala et al., 1986; Thanavala and Roitt, 1986). Immunization with anti-idiotypic 
antibodies against MMTV induced both cellular and humoral immunity in the mice. The 
internal image Ab2~ antibodies have been shown to induce specific immune responses to 
hepatitis B surface antigen in different species (Kennedy and Dressman, 1984; Kennedy and 
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Dressman, 1986; Kennedy et al., 1986; Thanavala et al., 1985). Anti-idiotypic antibodies 
may prove useful in developing vaccines against the AIDS virus (HIV). Anti-idiotypic 
antibodies have been generated that can induce anti-HIV responses specific for glycoproteins 
on HIV (gp41, gp120, and gp160) (Zhou et al., 1987; Zhou et al., 1990). Tackaberry et al. 
have shown an anti-Id antibody that mimicked a neutralizing epitope on the glycoprotein b 
complex of human cytomegalovirus and acted as a network antigen for inducing a specific 
anti-human cytomegalovirus antibody response (Tackaberry et al., 1993). Jackson et al. 
(1990) have demonstrated that it is possible to expand the use of anti-idiotypic vaccines for 
diseases in which the primary target is a mucosal tissue, such as the lung or gut, by using oral 
immunization. 
In addition to protein antigens, anti-idiotypic antibodies may prove exceptionally beneficial 
in developing vaccines against carbohydrate, lipid, or nucleic acid epitopes ( or even drugs). 
In these cases, the anti-idiotypic antibody is a protein that mimics a nonprotein epitope. For 
example, rodent anti-idiotypic antibodies have been generated to the parasites Trypanosoma 
rhodesiense, Trypanosoma cruzi, and Shistosoma mansoni (experimental schistosomiasis). 
As previously mentioned, parasites often have carbohydrate epitopes, limiting the 
development of vaccines by busing recombinant technology. Anti-idiotypic antibodies may 
circumvent this problem (Burdette and Schawartz, 1987; Grzych et al., 1985; Sacks et al., 
1985). Anti-idiotypic antibodies have also been made against lipid epitopes. The thymus-
independent antigen lipid A [from Eikenella corrodens lipopolysaccharide (LPS)], was 
converted into a thymus-dependent immunogen by developing an anti-idiotypic antibody 
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against lipid A. Mice previously immunized with the anti-idiotypic antibodies survived when 
they were given a lethal dose of LPS (Kato et al., 1990). 
Anti-idiotypic vaccines also have some potential complications. It is unknown how long anti-
idiotypic immunity will last. As with other therapeutic or diagnostic antibodies, humans may 
develop an anti-rodent monoclonal antibody response against the anti-idiotypic antibodies. 
Humanization of the anti-idiotypic antibodies by recombinant DNA techniques may be 
necessary to prevent this. Also, care must be taken when choosing the antibody for the 
vaccination, since different anti-idiotypic antibodies raised against the same idiotope can 
have different or even opposite physiological effects. For example, anti-idiotypic antibodies 
(Ab2) were raised against an antibody (Abl) reactive with a carbohydrate moiety on group A 
streptococci. Injection of Ab2 oflgG 1 class protected the mice against infection by group A 
streptococci; both humoral and cell-mediated immunity were induced. In contrast, injection 
of Ab2 of the IgG2 class suppressed the humoral immune response against the bacteria 
(Dreesman and Kennedy, 1985; Eichmann and Rajewsky, 1975). 
2. Idiotypic manipulation of tumor immunity 
The administration of anti-Id antibodies as surrogate tumor-associated antigens represents 
another potential application of the Id vaccine concept. Both T cells and B cells express 
idiotopes on their antigen-specific receptors (the T cell receptor or surface lg receptor). In 
fact, T cell receptors and lg receptors can even share idiotopes. Theoretically, anti-idiotypic 
antibodies against unique idiotopes on Tor B cell cancers (such as lymphomas, leukemias, or 
myelomas) can be used to eradicate the cancer. In a specific embodiment of the invention, 
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internal image antibodies with tumor antigen activity can be used as tumor "vaccines" 
towards induction of specific tumor immunity. For example, such vaccines can be 
therapeutically valuable for patients whose primary neoplasms have been removed but who 
are at risk for development of metastases. One of the major problems of cancer therapy is 
immune tolerance, which can be easily overcome by an appropriate anti-Id vaccine as 
compared to a typical multivalent vaccine consisting of whole cells, lysates or antigen-rich 
supernatant (Bhattacharya-Chatterjee et al., 2000). Several idiotypic manipulations of tumor 
immunity have been reported and anti-tumor immunity has even been elicited in 
experimental animals by injecting with anti-idiotypic expressing internal images of putative 
tumor-specific antigens (Bona, 1989; Victor-Kobrin et al., 1989). Nepom et al. (1984) 
described induction of tumor immunity where an oncofetal antigen was introduced into a 
xenogeneic host. Polyclonal anti-idiotypic antibodies were prepared which recognized 
idiotypic determinants on a mouse antibody to the p97 c epitope of human melanoma antigen 
p97. The polyclonal antisera could induce, in mice, both CMI and an Ab3 response to p97. 
Forstrom et al. (1983) used an anti-idiotypic antibody to induce CMI in mice to a syngeneic 
chemically induced sarcoma. In this study, the anti-idiotypic antibody was an autoantibody 
produced by hyperimmunization to the tumor, and the tumor antigen was not a defined 
molecule. Several studies demonstrated idiotypic manipulations of tumor immunity in 
syngeneic systems, with undefined antigen molecules (Binz et al., 1982). Flood et al. (1980) 
showed evidence that murine anti-idiotypic T lymphocytes could participate in an 
autoimmune reaction to fibrosarcoma-specific T lymphocytes, and thus adversely affect an 
individual's immune response to a tumor. Binz et al. (1982) used anti-idiotypic antibodies to 
induce in vitro proliferation of T lymphocytes specifically cytotoxic to rat sarcoma cells. 
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Anti-Id responses have been implicated in the induction of anti-tumor immunity to colorectal 
cancer (Koprowski et al., 1984). Clinical trials in human colorectal patients with a polyclonal 
anti-Id raised against the MAb 17-lA that recognizes a colon cancer-associated Ag have 
shown anti-tumor antibody responses (Herlyn et al., 1987). In another study, it was 
demonstrated that intradermal injection of 2 mg of anti-Id MAb MK2-23, which mimics a 
high molecular weight human melanoma antigen, elicited anti-tumor antibody responses in 
melanoma patients (Mittelman et al., 1992). Additional studies have looked at the effect of 
anti-idiotypic antibodies on tumor growth. Tilkin et al. (1981) showed that immunization of 
mice with lymph node cells sensitized to an unidentified sarcoma antigen resulted in tumor 
rejection and growth inhibition. Kennedy et al. (1985) described the suppression of tumor 
formation in mice challenged with SV 40-transformed cells, after injection with polyclonal 
anti-idiotypic antibodies related to the SY 40 antigen. Koprowski et al. (1984) showed the 
presence of anti-idiotypic antibodies in patients who had a remission of carcinoma after 
administration of a monoclonal antibody directed against human gastrointestinal cancer. 
In an analysis of idiotopes associated with the response to MCA-induced mouse sarcomas or 
carcinomas (Lee et al., 1986), immunization with monoclonal Ab2 failed to generate Ab3 
with Abl-like specificity, whereas antitumor T helpe cell was easily induced. This 
observation, coupled with the finding of idiotype-positive T helper cell in the naturally 
occurring anti tumor response, supports a model in which there can be a direct regulatory 
interaction between Id+ T cells and anti-idiotypic B cells (and Ab2) (Bismuth, et al., 1984; 
Nelson and Nepom, 1986; Thomas et al., 1983). In vivo, the Id+ T cells can provide the 
stimulus for production of anti-idiotype. The lack of Id+ B cell recognition in certain cases 
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may reflect a defect in the genetic capacity to generate anti tumor idiotopes on 
immunoglobulin molecules; alternatively, the regulatory state in the tumor-bearing host may 
effectively suppress Id+ Ab 1. In addition to idiotypic interactions which result in a T helper 
cell response leading to tumor rejection, exposure to tumor antigen (or antigen-antibody 
complexes) can lead to the generation of antigen-specific suppressor T cells (Ts). In several 
tumor systems, suppressor T cells have been shown to function as inducer cells, triggering 
and amplifying tumor antigen-specific suppression (Nepom et al., 1983). 
In a study on the analysis of Igh-restricted T cell responses to the hapten azobenzenearsonate, 
the nature of immunoglobulin idiotopes was found to determine the development of T S 
idiotopes (Hayglass et al., 1986). T cells developing in Igh congenic mice acquired the 
idiotypic repertoire of the host, and treatment of neonatal animals with antibodies to the 
immunoglobulin chain abolished the establishment of a normal repertoire of functional T cell 
idiotypes. Thus, the immunoglobulin compartment could determine the development of 
complementary T cell recognition elements. 
3. Reactions of Anti-Id antibodies with cellular receptors 
The anti-idiotypic approach is a powerful strategy that allows the construction ofreceptor-
directed probes without prior isolation of the target receptor. This approach has interested 
many investigators who study the properties of cell-surface receptors. A major reason is that 
it is possible, by this method, to generate antireceptor antibodies without using the receptor 
as the immunogen (Erlanger et al., 1986). Because receptors are often difficult to isolate in 
sufficient quantity for use as an immunogen this alternative approach has a very practical 
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application (Nisonoff, 1991). The approach has been successfully used for a wide spectrum 
of recipient proteins including hormone receptors (Linthicum et al., 1988), ion channels 
(Kleyman et al., 1991), coagulation factors (Vogel et al., 1990), transport proteins (Pain et 
al., 1990), and retention proteins (Vaux et al., 1990). In particular, the anti-idiotypic route has 
proven useful for many receptors of biologically active peptides including insulin (Sege and 
Peterson, 1978), thyroid-stimulating hormone (Frid et al., 1982), angiotensin II (Couraud, 
1987), ~-endorphin (Gramsch et al., 1988), substance P (Couraud et al., 1985), morphine 
(Glasel, 1989), and bradykinin (Hassemann et al., 1991) and pathogens including reovirus 
(Gaulton et al., 1985; Nepom et al., 1982;), leukemogenic retrovirus (Ardman et al., 1985), 
and herpes simplex (Huang et al., 1996). 
4. Anti-id antibodies as diagnostic reagents 
Even though the notion of antigen mimicry by anti-Id has been confirmed by several 
laboratories for numerous diverse antigens, the utility of anti-Ids as surrogate antigens in 
diagnostic immunoassays has received little attention. Nevertheless, they are extremely well 
suited to this application for both competitive immunoassay formats and direct serologic 
assays for specific antibody. Anti-Ids are promising alternatives to the many antigens that are 
not appropriate for the large-scale production and/or purification required for components of 
commercial immunoassays. 
To overcome the limitations of conventional antigens, internal image anti-Ids can be used in 
place of antigen in competitive immunoassays (Jiang et al., 2003; Potocnjak et al., 1982; 
Zhou and Kisil, 1995). Anti-Ids, like any antibody, can be safely produced and purified in 
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large quantities, can have multiple sites for the attachment of label, can be labeled without 
substantially diminishing their stability or ability to compete with antigen, and can be bound 
to a solid support without appreciable loss of immunoreactivity (Walter et al., 1988). For 
many of the same reasons, anti-Ids are also well suited for use in noncompetitive serologic 
assays as direct replacements for native antigen in tests for the presence of specific antibody 
(Lin and Zhou, 1995; Zhou, 1999). Anti-idiotypic antibodies have been used as 
serodiagnostic reagents to detect antibodies against viruses such as hepatitis B virus (Irshad 
et al., 1987; Kennedy and Dressman, 1983; Kim et al., 1989), human cytomegalovirus 
(Tackaberry et al., 1993), psuedorabies virus (Zhou et al., 1994), bluetongue virus (Zhou and 
Huang et al., 1995; Zhou and Lin, 1997; Zhou, 1999), influenza virus (Betakova et al., 1998), 
PRRSV (Jiang et al., 2003, Zhou et al., 2004); bacteria such as Mycoplasma capricolum 
(Benguric et al., 2001), Vibrio anguillarum (Yongjuan et al., 2002), parasites such as 
Schistosoma mansoni (Percy and Ham, 1988), Trypanosoma cruzi (Reis et al., 1993), 
Entamoeba histolytica (Chavez-Rueda et al., 2002), bovine cysticercosis (Hayunga et al., 
1992), hormones such as insulin (Casiglia et al., 1991) and allergens such as ryegrass pollen 
allergen (Zhou et al., 1991). 
It is not unreasonable to ask whether autologous anti-Id that may be present in blood or 
serum samples would interfere in anti-Id-based immunoassays. Data from early experiments 
on auto anti-idiotypic antibodies indicate that internal-image anti-Ids that represent the 
configuration of the original antigen are rarely found (Kluskens and Kohler, 1974; Huang et 
al., 1988). However, anti-Ids that participate in the regulation of immune responses do arise. 
These types of anti-Id are termed regulatory anti-Ids, and in general they are not internal 
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images. Thus, it appears that internal-image anti-Ids do not represent a major portion of the 
immunoregulatory network. They are therefore not expected to be present in levels high 
enough to interfere with assay performance. 
In conclusion, the immune network hypothesis offers a unique approach to transform epitope 
structures into Id determinants expressed on the surface of antibodies. According to this 
original network hypothesis, the Id-anti-Id interactions regulate the immune response of a 
host to a given antigen. Immunization with a given Ag will generate the production of 
antibodies against this Ag termed Ab 1. This Ab 1 can generate a series of anti-Id antibodies 
against Abl termed Ab2. Some of these Ab2 molecules can effectively mimic the three-
dimensional structures of external Ags. These particular anti-Ids called Ab2~, which fit into 
the paratopes of Ab 1, can induce specific immune responses similar to responses induced by 
nominal Ag. Anti-Id antibodies of the~ type express the internal image of the Ag recognized 
by the Ab 1 antibody and can be used as surrogate Ags. Immunization with Ab2~ can lead to 
the generation of anti-anti-Id antibodies (Ab3) that recognize the corresponding original Ag 
identified by the Ab 1. Several such Ab2~ have been used in animal models to trigger the 
immune system to induce specific and protective immunity against bacterial, viral, and 
parasitic infections. The administration of Ab2~ as surrogate tumor-associated Ags 
represents another potential application of the Id vaccine concept. Furthermore, the technical 
and commercial advantages of anti-Ids make them excellent alternatives to many 
conventional antigens for diagnostic immunoassays. 
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CHAPTER 2. Monoclonal Anti-Idiotypic Antibody Specific for Antibodies Against GPS 
Antigen of Porcine Reproductive and Respiratory Syndrome Virus Elicits Specific 
Immune Response in Mice 
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Abstract 
A syngeneic mouse monoclonal anti-idiotypic antibody (anti-Id), designated M8G, was 
generated against a monoclonal antibody (MAb 25C) specific for porcine reproductive and 
respiratory syndrome virus PRRSV glycoprotein 5 (GP5). Observations that (i) the anti-Id 
inhibited the binding of MAb 25C to PRRSV antigen, and (ii) the Id-anti-Id interaction could 
be inhibited by PRRSV antigen indicated that the Id was located within or near the antigen 
combining site. These properties served to characterize M8G as an internal image anti-Id. 
Evidence that an immune response in pigs experimentally infected with PRRSV elicits the 
formation of antibodies that express a common Id was provided by the observation that the 
Id-anti-Id interactions could be inhibited by pig antisera to PRRSV antigen. The anti-anti-Id 
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antibodies (Ab3) induced with monocolonal anti-Id (MAb2) competed with MAbl binding to 
PRRSV antigen. Furthermore, the binding of anti-anti-Id to MAb2 was inhibited with 
PRRSV antigen, indicating that anti-anti-Id mimics the structure of the epitope in GP5 that 
was recognized with MAbl. These serologic findings suggest that MSG carries the internal 
image of the antigen. 
Introduction 
Porcine reproductive and respiratory syndrome (PRRS), caused by the PRRS virus (PRRSV), 
is currently among the most significant pathogens of swine worldwide. PRRSV is a member 
of the family Arteriviridae in the order Nidovirales (6). PRRSV is an enveloped RNA virus, 
and has a 15-kb positive-sense, single-stranded RNA genome. PRRSV encodes an 
approximately 4,000-amino-acid large replicase polyprotein (open reading frame [ORF] la 
and 1 b) and six structural proteins of 130 to 265 amino acids (ORFs 2 to 7) (9,32). Three of 
these structural proteins have been identified as envelope (25 kDa), matrix (19 kDa), and 
nucleocapsid (15 kDa) proteins, i.e. GP5, M, and N proteins, respectively (1,2,22). Three 
additional proteins with molecular masses of 29-30 kDa (GP2), 45-50 kDa (GP3), and 31-
35 kDa (GP4) have been identified in purified Lelystad virus and are presumed to be 
associated with the viral envelope (10,22,23,36). Among these viral proteins, GP5 is the 
major envelope protein and serum neutralizing antibody titers were significantly correlated 
with anti-GP5 titers (29,31,35,37). The humoral immune response is presumed to play an 
important role in resistance to reinfection and in prevention or reduction of viral spread from 
animal to animal, since neutralizing antibodies have the potential to clear free virus from the 
circulation (25). 
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Anti-PRRSV immunoglobulins in serum after PRRSV infection can be detected within 7 
days of infection. (20,25,26,30,38). Neutralizing antibodies to PRRSV develop between 1 
and 2 months following exposure (11,20,24,26,38). Anti-PRRSV antibodies may persist in 
blood for the lifetime of commercial pigs (25), and PRRSV can persist in some animals 
despite high levels of antiviral antibodies which is associated with long-term, intermittent 
shedding or seminal excretion of the virus (7,13). 
An idiotope is a single antigenic determinant that is located on the variable regions (V 
domain) of both antibody molecules and receptor molecules of T and B lymphocytes. 
Idiotopes may be either in the antigen binding site or on the framework regions of the 
variable domain. The sum of the idiotopes on an antibody's V domain determines its 
idiotype. The idiotype (Id) network theory of immune regulation offered by Jeme (15), 
propose that the immune response to a given antigen can be regulated by a series ofld and 
its serological counterpart, an anti-idiotypic antibody (anti-Id or Ab2), has been found useful 
for the production of diagnostic reagents and vaccines (19). Upon immunization with an 
idiotypic antibody (Ahl), the corresponding anti-Ids are elicited and can be serologically 
classified into four categories (Ab2a, Ab2~, Ab2y and Ab2£) (4,16). Ab2a recognizes an Id 
associated with the framework region of Ab 1. Ab2~, an internal image anti-Id Ab2, 
recognizes an Id within the antigen-combining site and bears a structural resemblance to the 
original antigen. The anti-Id mimicry of the original antigen has been experimentally proved 
in many virus systems (19,28,39). Ab2y, like Ab2~, recognizes an Id within the antigen-
combining site but does not carry the internal image of the original antigen. Ab2£ is defined 
as the antibody that binds both Ahl and antigen (4). A given idiotypic antibody is under the 
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control of an anti-Id, whereas the anti-Id can be regulated by anti-anti-Id (or Ab3). The 
concept of internal image stems from the possibility of raising Ab3 antibodies that would 
recognize the original Ag. If one takes into account both the specificity and the idiotypic 
characteristics of Ab 1 molecules, four discrete types of Ab3 molecules may be anticipated: 
Id-Ag-, Id+ Ai, Id-Ag+ and Id+ Ag\ the later being very similar to Ahl and termed Ahl' (8). 
PRRSV infection poses a challenge to current serodiagnostic and vaccination strategies. 
Because the genetic diversity of field PRRSV isolates is very high, vaccine efficacy against 
heterologous challenge may be limited (34). Also, live PRRSV vaccines have been observed 
to revert to virulence (5,33), and the safer, killed vaccines have so far proved less effective 
(27). A better understanding of the mechanisms that regulate immunity to this virus will aid 
in the development of more effective vaccines. 
In this study, we describe the generation and characterization of a monoclonal anti-Id 
produced against a mouse MAb specific for GP5 of PRRSV and determined the structure of 
Ab3 (Id+ Ag+ or Id+ Ag l The monoclonal anti-Id was classified as Ab2~ preparation. 
Immunization with Ab2~ induced an anti-GP5 response. Serologically, the anti-anti-Id 
antibodies (Ab3) induced with anti-Id MAb2 competed with Ahl binding to PRRSV antigen, 
inhibited the Id-anti-Id reaction, and expressed a similar Id present on the mouse monoclonal 
Ahl. These results indicate that an Id-anti-Id network may be operational in modulating the 
immune response to GP5 in PRRSV infection. 
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Materials and Methods 
PRRSV antigen. A cell line, MARC-145 was infected with VR-2332 of PRRSV isolate at a 
multiplicity of infection of approximately 5 and the infected cell culture was then incubated 
and harvested as described by Yoon et al. (38). The total protein concentration of the crude 
cell culture antigen preparation was determined by the method of Lowry et al. (21) using a 
protein assay kit (Pierce, Rockford, IL). 
Preparation of MAbl. Hybridoma cells secreting MAbl specific for the PRRSV 
glycoprotein (GP5), which is denoted as 25C (IgG1, 11,), was originally developed by Yang et 
al. (37). The 25C-IgG was purified from supernatant ofhybridoma culture using ammonium 
sulfate precipitation method (14). IgG concentration was estimated at 280 nm using a 
spectrophotometer (SmartSpec 3000, Bio-Rad Laboratories, Hercules CA) with the extinction 
coefficient of 1.35. The purity of antibodies was confirmed by SDS-PAGE. 
Enzymatic digestion of the MAbl. To prepare F(ab')2, the purified 25C-IgG was digested 
using pepsin (Sigma, St. Louis, MO) as described previously (17,41). The F(ab')2 fragments 
were then purified by the Protein A affinity column to remove Fe fragments. SDS-PAGE and 
ELISA were used to confirm purity of F(ab')2. 
Pig sera. Serum samples were collected from a group of pigs experimentally infected with 
PRRSV. The presence of anti-PRRSV antibodies was confirmed by IF A and HerdCheck 
ELISA as described previously (17,41). 
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Production of MAb2 specific for GPS of PRRSV. Six week-old female BALB/c mice, 
were immunized intraperitoneally (IP) with 25C-F(ab')2-KLH (50 µgin 100 µ1 of0.01 M 
PBS) mixed with Complete Freund's Adjuvant (Sigma, St. Louis, MO) followed by two 
injections of 25C-F(ab')2-KLH (50 µgin 100 µ1 of PBS) mixed with Incomplete Freund's 
Adjuvant (Sigma, St. Louis, MO) on day 14 and 28. Blood was taken from each mouse and 
the antibody response was measured by ELISA (as described below). The mouse with the 
highest antibody titer in its serum was selected as the spleen donor and was given an 
intravenous booster injection of 0.1 ml of 25C-F(ab')2-KLH in PBS, 3 days before fusion. 
The spleen cells from the immunized mouse were fused with SP2/O myeloma cells, as 
described elsewhere (18). Hybridoma culture supematants were examined for the presence of 
antibody by using 25C-F(ab')2 fragments at 2 µg/ml (100 µ1/well) in sodium phosphate buffer 
(PBS; 10 mM, pH 7.2) in an ELISA format. Hybridomas that reacted positively were cloned 
by the limiting dilution method. A monoclonal anti-Id, designated MSG, was identified as an 
IgG 1 (K) using the mouse IsoStrip kit (Boehringer Mannheim, Indianapolis, IN). IgG 
concentration was estimated at 280 nm using a spectrophotometer (SmartSpec 3000, Bio-Rad 
Laboratories, Hercules CA) with the extinction coefficient of 1.35. The purity of antibodies 
was confirmed by SDS-PAGE. 
Labelling Antibodies. Conjugation ofMAbl (25C) to Biotin and MAb2 (MSG) to 
Horseradish Peroxidase (HRP) were performed based on the documentation protocol by the 
manufacturer (Pierce, Rockford, IL). Optimum dilutions of the conjugates were determined 
using ELISA and W estem blot assay. 
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Enzymatic digestion of the MAb2. MAb2-F( ab')2 was prepared based on the protocol 
described for making MAbl-F(ab')2 . A papain digestion was performed to prepare MAb2-
Fab using protocol described elsewhere (14). The Fab fragments were purified using a 
Protein A affinity column and Fe fragments were removed. The purity ofFab was confirmed 
using SDS-PAGE and ELISA. 
Production of anti-anti-idiotypic antibody (Ab3) specific for GPS of PRRSV. For 
induction of Ab3, MAb2 was used in the form ofFab coupled to KLH (Fab-KLH). Three, 
six week-old female BALB/c mice were immunized intraperitoneally on day 0, with 50 µg of 
MabrFab-KLH (50 µgin 100 µ1 of PBS) emulsified 1:1 in Freund's complete adjuvant 
(Total vol.= 0.2 ml). Two booster injections were given on days 14 and 28 each with 50 µg 
of the same anti-Id preparation in Freund's incomplete adjuvant. Two weeks after the final 
injection, mice were bled and serum samples tested for the presence of anti-anti idiotypic 
antibody (Ab3) in serum by an ELISA with MAb2-Fab on solid-phase. The antibody end 
point titre (EPT) was expressed as the highest serum dilution that gave the absorbance at 490 
nm 3-fold higher than that for pre-immune serum. 
Characterization of monoclonal anti-idiotypic antibodies specific for GPS 
a) Indirect ELISA. An indirect ELISA was used to detect the direct binding between 
MAb2-M8G and MAbl-25C. The solid phase was prepared by coating the wells of ELISA 
plates with 25C-F(ab')2 at 2 µg/ml (100 µl per well) in PBS (0.01 M, pH 7.2) at 4°C 
overnight. As a control, normal mouse F(ab')2 (Pierce, Rockford, IL) and two other 
monoclonal antibodies against matrix and nucleoprotein of PRRSV designated as 19Bd and 
79 
15E, respectively were similarly used. After removal of excess antibodies by washing the 
plate with PBS containing 0.05 % ofTween-20 (PBS-T, v/v) three times, purified M8G at 
different concentrations was added to the wells (100 µ1 per well) and incubated for 45 min at 
room temperature. The wells were then washed three times with PBS-T. The MAb2 that had 
bound to the MAbl was detected by adding HRP-goat anti-mouse Fey (Jackson 
ImmunoResearch, West Grove, PA) at 1 :2000 dilution in PBS-T to each well and the plate 
was incubated for 45 min at room temperature. After washing the wells with PBS-T, the 
substrate o-phenylene diamine (OPD, 100 µI/well; Sigma, St. Louis, MO) was used to 
develop the calorimetric reaction. Finally, stop solution (H2SO4, 3 M) was added to each well 
at 100 µ1 per well. The optical density (OD) at 490 nm of each well was measured on an 
automatic ELISA plate reader (Universal Microplate Reader, EL800, Bio-Tek Instrument, 
Inc., Winooski, VT). The assay was performed in duplicate. 
b) Western blot analysis. To further confirm the specificity ofM8G for 25C Western blot 
immunoassays was performed based on a previously developed method ( 40) with the 
following modification: 5 µg/lane of 25C-IgG or normal mouse IgG (as a control) were 
loaded on the SDS-PAGE under both reducing and non-reducing conditions and then 
transferred to PVDF membrane (Bio-Rad Laboratories, Hercules, CA). The membrane was 
blocked with 1 % BSA (w/v) in PBS-Tat room temperature for 1 hand incubated with HRP-
M8G at 1: 1000 dilution for another hour. The membrane was washed three times with PBS-T 
and then two times for 5 minutes with PBS (pH 7.2) to remove the detergent. Finally, 3,3'-
diaminobenzidine tetra hydrochloride (DAB) liquid substrate system (Sigma, St. Louis, MO) 
was added to develop the color reaction. 
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c) Competitive ELISAs. To determine whether swine antisera (Abl) could inhibit MAbl 
binding to MAb2 a competitive ELISA (C-ELISA) was employed. The solid phase was 
prepared by coating the wells of microtiter plates (Nalge Nunc International, Roskilde, 
Denmark) with M8G-F(ab')2 (0.2 µg/well). The biotinylated 25C (1/10000 dilution) was used 
in the liquid-phase with or without mixing with individual competitors including swine 
serum recovered from pigs that had been experimentally infected with PRRSV (at 1/10 and 
1/100 dilution). The conjugate used in the C-ELISA was HRP-Streptavidin (Jackson 
IrnmunoResearch, West Grove, PA) at 1:2000 dilution. The addition of the substrate and 
quantitation of the calorimetric reaction was performed as described above. The percent 
inhibition was calculated by the following formula: 
% INHIBITION= [l - (OD490 with competitor - background OD490) / (OD490 without 
competitor - background OD490)] x 100. 
To determine whether PRRSV antigen could inhibit MAbl binding to MAb2, a C-ELISA 
was performed basically the same as described above, except that purified 25C- F(ab')2 
(0.2 µg/well) was used to coat the ELISA plate. M8G-HRP (at a final concentration of 
1 :2000) was used in the liquid-phase with or without mixing with individual competitors 
including PRRSV antigen and MARK 145 cell line as a control at 1000, 100 and 10 µg/ml. 
the rest of assay was performed as described above. 
d) IFA. To ascertain whether the anti-Id could bind to antibody against GP5 and inhibit its 
binding to PRRSV, an indirect immunofluorescence assay (IFA) was employed. The IFA 
performed was based on the procedure described elsewhere (Yoon et al., 1995). In brief, 
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MARC-145 cells cultured on slides were infected with VR-2332 strain of PRRSV. After 
culturing for 2 days, the infected cells were fixed and probed directly with MAb against GP5 
(25C) (4 µg/ml) or premixed with M8G (at different concentrations). Normal mouse IgG was 
used as a control. Binding of 25C to PRRSV was visualized using goat anti-mouse IgG 
coupled with fluorescein isothiocyanate (FITC, 1/50 dilution; Jackson ImmunoResearch, 
West Grove, PA). 
Characterization of anti-anti-idiotypic (Ab3s) antibodies specific for GPS 
a) Detection of Ab3. An I-ELISA was used to determine the specificity of the binding of 
serum Ab3 antibodies to MAb2 (M8G). The solid phase was prepared by coating the wells of 
ELISA plates with M8G-F(ab')z fragments at 2 µg/ml (100 µ1/well) in PBS (10 mM, pH 7.2) 
at 4 °C overnight. After washing the plate with PBS-T, individual mouse serum diluted 
1: 100, 1: 1000, or 1: 10000 in PBS-T were added to duplicate wells (100 µ1/well) and 
incubated for 45 min at room temperature. The wells were, then washed three times with 
PBS-T and the presence of Ab3 that bound to the solid-phase M8G-F(ab')2 was detected by 
the addition ofHRP-goat anti-mouse Fey diluted 2000-fold in PBS-T (100 µ1/well) for 
45 min at room temperature. After final washing with PBS-T for three times, substrate 
solution (OPD, 100 µ1/well) was added to all wells to develop the colorimetric reaction at the 
room temperature for 15 min. The reaction was then stopped by adding 3 M H2SO4 to each 
well (100 µ1/well) and read at OD 490 nm on an automatic ELISA plate reader. 
b) Competitive ELISAs. AC-ELISA was performed to determine whether Ab3 could 
inhibit MAbl binding to MAb2. For this purpose, the solid phase was prepared by coating 
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the wells of ELISA plate with M8G-F(ab')2 (0.2 µg/well) . The Biotin-25C (1 /10000 dilution) 
was used in the liquid-phase with or without mixing with individual mice sera immunized 
with M8G, at 1/10 and 1/100 dilution. A hundered microliter of the mixture were added to 
the wells and kept for 1 hat room temperature followed by washing three times with PBS-T. 
The conjugate used in the C-ELISA was HRP-Streptavidin (Jackson ImmunoResearch, West 
Grove, PA) at 1 :2000 dilution in PBS-T (100 µI/well). The rest of assay was performed as 
the same described previously. 
To determine whether PRRSV antigen could inhibit MAb2 binding to Ab3, a C-ELISA was 
performed basically the same as described above, except that individual purified M8G-
F( ab')2 (0.2 µg/well) was used to coat the ELISA plate. The mouse serum (Ml, at the final 
concentration of 1: 1000) was used in the liquid-phase with or without mixing with individual 
inhibitors including PRRSV antigen and MARK 145 cell line as a control at 1000 and 100 
µg/ml. After washing the plates 3 times with PBS-T, HRP-goat anti-mouse Fey (Jackson 
ImmunoResearch, West Grove, PA) diluted 2000-fold in PBS-T (100 µI /well) for 45 min at 
room temperature was used. The addition of the substrate and quantitation of the calorimetric 
reaction was performed as described above. 
To further confirm the specificity of Ab3 for PRRSV, the ability of Ab3 to inhibit Ahl from 
binding to the solid-phase PRRSV antigen was tested by competitive ELISA. For this 
purpose 96-well microtiter plates were coated with PRRSV Ag (100 µI/well) at 2 µg/ml in 
PBS (0.01M, pH 7.2) and incubated over night at 4°C. The Biotin-25C (1 /10000 dilution) 
was used in the liquid-phase with or without mixing with individual mouse sera at 1/10 and 
1/100 dilution. Pre-immune serum was used as a control. A hundered microliter of the 
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mixture was added to the wells and kept for 1 h at room temperature followed by washing 
three times with PBS-T. The conjugate used in the C-ELISA was HRP-Streptavidin (Jackson 
ImmunoResearch, West Grove, PA) at 1 :2000 dilution in PBS-T (100 µ1/well). These values 
were compared with the maximum binding of the Ab 1, which occurred in the absence of a 
competitor. The percent inhibition was calculated using the formula described above. 
Results 
Characterization of monoclonal anti-idiotypic antibody specific for GPS 
Specificity of the monoclonal anti-Id MSG. The specificity of the mouse monoclonal anti-
Id MSG was tested by two different assays. First, an I-ELISA was employed (Fig.I). The 
lowest concentration ofM8G that bound to solid-phase 25C was 1.56 µg/ml. Monoclonal 
anti-Id did not bind to other F(ab')2 fragments of monoclonal antibodies directed to PRRS 
virus M protein (19Bd) or nucleoprotein (15E) or to normal mouse F(ab')z. 
In addition, Western blot analysis was employed to confirm the immunoreaction between 
Mab 1 and Mab2. As shown in Fig.2, membrane-bound 25C reacted with MSG. It should be 
noted that monoclonal anti-Id did not react with membrane-bound normal mouse IgG. The 
results of Western blot showed that the monoclonal anti-Id recognizes the idiotype associated 
with both heavy and light chains of the MAb 1 (Fig.2). 
Monoclonal anti-Id recognizes an Id common to antibodies to GPS of PRRSV. The 
ability of pig antisera to inhibit 25C from binding to monoclonal anti-Id was determined 
using a C-ELISA. As shown in Table 1, antisera from pigs experimentally infected with 
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PRRSV, inhibited 25C from binding to the solid-phase M8G. The degree of inhibition with 
antisera from pigs experimentally infected with PRRSV was 20.4 ± 1.1 to 29.5 ± 0.8, which 
may simply be because these pigs infected with whole virus were not expected to produce 
high titer antibodies against GP5 of PRRSV as detected by SN (data not shown). 
Monoclonal anti-Id possesses the characteristics of an internal image anti-Id. The anti-Id 
M8G was examined to determine if it possessed the properties of an internal image anti-Id, 
i.e. whether or not: (i) the binding of 8MG to 25C could be inhibited by PRRSV antigen and 
(ii) anti-Id M8G could inhibit the binding of 25C to PRRSV antigen. 
AC-ELISA was performed to find out whether PRRSV antigen could inhibit 25C binding to 
M8G. As shown in Fig. 4, the degrees of inhibition were found to be antigen concentration 
dependent. In the presence of PRRSV antigen at the final concentration of 500 µg/ml, the 
binding of anti-Id M8G to solid phase 25C was inhibited by 83%, whereas 22.6% inhibition 
was achieved with MARK 145 cell line at the same concentration (Fig.3) . 
An IFA was employed to determine whether MAb2 could inhibit MAbl binding to PRRSV. 
In the presence of M8G (100 µg/ml), the binding of 25C to PRRSV was inhibited to the 
extent of 100% (Table 2). 
Together, these results indicated that M8G possesses the characteristics of an internal image 
anti-Id which recognizes the Id located within or near the antigen combining sites of the 
antibody to GP5 . 
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Characterization of anti-anti-idiotypic antibody (Ab3) specific for GPS 
Induction of anti-anti-Id antibody. Immunization with M8G in a syngenic system was 
done and the induced anti-anti-Id antisera (Ab3) were analyzed with an indirect ELISA. Fig.4 
shows the binding activities of three mouse serum immunized with M8G. 
Ab3 antibodies recognize the Ahl-specific epitope of GPS. To determine whether Ab3 
possessed Ab 1-like (Ab 1 ') properties with specificity for the PRRSV antigen, two 
competitive ELISA were performed. First a C-ELISA was used to determine whether 
PRRSV antigen could inhibit MAb2 binding to Ab3 . As shown in Fig. 5, PRRSV antigen 
compare to MARK 145 cell line, significantly (P<0.05) inhibited (73 and 53 % at 1000 and 
100 µg/ml, respectively) Ab3 binding to M8G. To further confirm the specificity of Ab3 for 
PRRSV antigen, the immune sera were tested additionally by the second immunoassay. A C-
ELISA was employed for the ability of immune serum (Ml) to inhibit Ab 1 (25C) from 
binding to the solid-phase PRRSV antigen. As shown in Fig. 6 the mouse serum compare to 
pre-immune sera significantly (P<0.05) inhibited the 25C-PRRSV interaction (at a dilution of 
1:10). 
Ab3 possess the Id of Ahl. To determine whether Ab3 expressed an Id of Abl, the immune 
sera were evaluated for their ability to inhibit 25C from binding to the solid-phase M8G-
F( ab ' )2 by a C-ELISA. As Table 3 shows, the percent of inhibition ofld-anti-Id reaction by 
immune sera ranged from 30 ± 1.5 to 86 ± 1.1. Pre-immune serum did not affect binding of 
25C to M8G. 
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The results show that murine Ab3 antibody recognized the same or a closely related epitope 
that is recognized by 25C. Also theses results confirm the fact that the MSG, carry the 
internal image of GP5 . 
Discussion 
This report describes the generation and characterization of a monoclonal anti-Id, designated 
as MSG, directed to an Id on monoclonal antibody, 25C. 25C recognized an epitope referred 
to as GP5 on the PRRSV (37). The finding that Id (25C)-anti-Id (MSG) interaction could be 
inhibited by swine antisera to PRRSV (Table 1) indicated that the Id is common to antibodies 
that are formed to GP5 in umelated species. Moreover, evidence was also obtained which 
revealed that the interaction between the Id-anti-Id could be inhibited by PRRSV antigen 
(Fig.3). These observations, along with the fact that monoclonal anti-Id inhibited the 
interaction between MAbl and PRRSV antigen (Table 2), indicate that MSG recognized an 
Id either within or near the antigen combining sites of 25C. According to the classification of 
anti-idiotypic antibodies (4), MSG has the characteristics of an internal image anti-Id. Since 
the antibodies to GP5 in the swine sera are of polyclonal origin and therefore are capable of 
recognizing any of the determinants of PRRSV e.g. Mand N proteins and or other 
glycoproteins (GP2, GP3, GP4), it is evident that only that fraction of the entire repertoire of 
antibodies which is (i) directed to GP5 of PRRSV and (ii) possesses the Id which is the same 
or similar to that 25C, has the capacity to inhibit the Id-anti-Id interaction. Therefore, it was 
not surprising to find that the swine sera were not able to completely inhibit the Id-anti-Id 
interaction (Table 1 ). 
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One prevailing concept in immunology developed from the idiotypic network theory (15) is 
that the immune response to a given antigen can be regulated by a series ofld-anti-Id 
interactions. The expression of a given Id is under the control of an anti-Id and the anti-Id can 
also be regulated by an anti-anti-Id. This complex set of interactions operates via a feedback 
mechanism to either enhance or suppress the immune response (i.e. formation of antibodies 
with a particular idiotype ). Our previous investigations on the immune response to PRRSV 
indicate the existence of the Id network (17,41). However, the role(s) of the Id-anti-Id 
networks in controlling the immune response to PRRSV is (are) not completely known at this 
time. 
In an anti-idiotypic cascade, the reference starting point is an antibody termed Abl, the 
combining site of which is reactive with a particular antigen and characterized by a set of 
idiotopes that collectively comprise its idiotype (Id). Polyclonal or monoclonal anti-Ids 
constitute an Ab2 population, which is used to induce an anti-anti-idiotypic or Ab3 response. 
If one takes into account both the specificity and idiotypic characteristics of Ab 1 molecules, 
four discrete types of Ab3 molecules may be anticipated: Id- Ag-, Id+ Ag-, Id- Ag+, Id+ Ag+ 
(8). The latter includes antibodies that resemble Ab 1 by reacting with the same antigen: they 
are designated Ab 1' and the Ab2 inducing them is termed the internal image of the antigen. 
To further study ofld network in PRRSV infection, monoclonal anti-Id (M8G) was used to 
induce an anti-anti-idiotypic antibodies or Ab3 response in murine model. The binding of 
anti-anti-Id induced to M8G was inhibited with PRRSV antigen (Fig.5). Furthermore, the 
anti-anti-Id antibodies (Ab3) induced with M8G, competed with Abl binding to PRRSV 
antigen (Fig. 6) indicating that anti-anti-Id mimics the structure of the epitope in GP5 which 
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was recognized with Ahl. Additionally, the facts that the binding ofMAbl to MAb2 was 
inhibited with Ab3 (Table 3), show that monoclonal anti-Id produced the anti-anti-Id that 
possessed Ab I-like (Ab 1 ') properties with specificity for the PRRSV antigen in murine 
model. 
The relationship between Ab 1 and Ab 1' antibodies has been explored in a number of 
different antigenic systems, and with either monoclonal or polyclonal anti-Id reagents (3). 
One result obtained consistently is that among Ab3 antibodies are some which do indeed 
closely resemble the Ab 1 in that they possess the same idiotopes, bind to the same antigen 
and derive from similar variable (V) genes. However, whilst the resemblance between Ab 1' 
and Ahl can be very close, many permutations ofresults have been seen. For example, 
binding of Ab3 to the antigen may not occur even although the same V-gene segments are 
selected, e.g. where the selection by anti-Id is directed towards the V segment rather than D 
and J idiotopes; or the affinity of Ab l' antibodies for antigen may be lower than that of the 
Ab 1, corresponding to differences in the complementarity determining region (CDR), 
particularly H3 sequences; or the Ab3 may bind a similar antigen, yet diverge considerably 
from the Ahl in V genes and CDRs. Thus, depending perhaps on the nature of the Ab2 
reagent, an Ab3 population can be more or less heterogeneous and include molecules with a 
range of fidelities to the Ab 1. 
According to Goldbaum et al. (12), there are two major possibilities for the induction of anti-
anti-Id (Ab3) that resemble Ahl. One is that a suitably selected anti-Id will mimic the antigen 
so closely as to produce the equivalent of an antibody response to the original antigen. A 
second possibility is that the anti-Id is specific for the Id and will thus stimulate lymphocytes 
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displaying anti-anti-Id immunoglobulins that should be identical or essentially identical to 
the Ab 1. In our study, results seem to favor the second hypothesis, since anti-GP5 Ab3 
showed greater binding equilibrium constants for the anti-Id than for the nominal antigen. 
The production and characterization of Ab3 confirms our findings that immunization with 
anti-GP 25C to modulate the idiotypic cascade by eliciting Ab2~ antibodies that, in tum, 
have the capacity to stimulate specific B cell clones to secrete Ab3 antibodies. Investigations 
using a murine model system are in progress to determine whether the anti-Id MSG can 
modulate the immune response to PRRSV. 
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FIGURE 1. Binding curve of monoclonal anti-Id-MSG to MAbl-25C F(ab')2 fragments. The 
solid phase was prepared by coating the wells of ELISA plates with 25C-F(ab')2 at 2 µg/ml. 
As a control, normal mouse F(ab')2 and two other F(ab')2 fragments of monoclonal antibodies 
against matrix (19Bd) and nucleoprotein (15E) of PRRSV were similarly used. After removal 
of excess antibodies by washing the plate, purified monoclonal anti-Id-MSG at different 
concentrations was allowed to react with solid-phase F(ab')2 fragments. Each point represents 

















FIGURE 2. Western blot analysis ofMAb2. MAbl-25C IgG (lanes 1 and 3) and normal 
mouse IgG (lanes 2 and 4) at 500 ng/lane were immobilized on PVDF membrane at both 
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FIGURE 3. Inhibition of the binding ofMAbl-25C to anti-Id-M8G-F(ab')2 fragments. 
PRRSV antigen along with MARK 145 cell control antigen at different concentrations, were 
used to inhibit biotinylated 25C binding to the solid-phase M8G. Data represent the mean 
(SEM) of percent inhibition obtained from duplicate ELISA results. 
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Table 1. Inhibition of binding ofMAbl to monoclonal anti-Id a by various pig Abls 
Pig no. Serum Dilution % Inhibition 
P3 1/10 25.6 
1/100 13.5 
P4 1/10 29.5 
1/100 19.6 
PS 1/10 20.7 
1/100 16.9 
P6 1/10 25.4 
1/100 15.5 
P9 1/10 20.4 
1/100 14.4 
Pre-immune 1/10 5.8 
1/100 3.3 
a Two hundred nanograms of MSG- F(ab')2 was coated to the solid phase and two different 
dilutions of individual swine antisera were used to inhibit the binding ofbiotinylated 25C to 
MSG. 
b Each number represents the mean (SEM) of the percent inhibition obtained from duplicate 
ELISA results. 
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Table 2: Inhibition of binding ofMAbl-25C to PRRSV by anti-Id 8G using IFA 
Inhibitor 100 µg/ml 50 µg/ml 25 µg/ml 12.5 µg/ml 
MAb2-M8G ++++a +++ ++ + 
NMigG - - - -
MAb against GP5 (25C) at 4 µg/ml premixed with anti-Id (M8G), and normal mouse IgG 
(NM IgG) at different concentrations were added to the infected cells with PRRSV cultured 
on slides. Binding of 25C to PRRSV was visualized using FITC-goat anti mouse IgG. 
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FIGURE 4. Binding curves of mice immune sera to monoclonal anti-Id MSG. Immune sera 
from mice immunized with anti-Id M8G-Fab were diluted in PBS-T and tested for binding to 
the solid phase M8G-F(ab')2 by an indirect ELISA. Each point represents the mean value 
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FIGURE 5. Inhibition of the binding of mouse immune serum (Ml) to anti-Id M8G-F(ab')2 
fragments. PRRSV antigen along with MARK 145 cell control antigen at different 
concentrations, were used to inhibit binding of muse serum immunized with M8G to the 
solid-phase M8G. Each point represents the mean value (SEM) of the OD490 obtained from 
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FIGURE 6. Inhibition of the binding ofMAbl-25C to PRRSV antigen. Immune serum from 
mouse immunized with monoclonal anti-Id MSG (Ml) at different dilutions, were used to 
inhibit MAb l-25C binding to the solid-phase PRRSV antigen. Each point represents the 
mean value (SEM) of the OD490 obtained from duplicate ELISA results. 
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Table 3. Inhibition ofld-anti-Id a reaction by mouse immune serum (Ab3) 
Pig no. Serum Dilution % Inhibition 
Ml 1/10 86 
1/100 25 
M2 1/10 39 
1/100 14.3 
M3 1/10 30 
1/100 10.5 
Pre-immune 1/10 3.3 
1/100 1.8 
a Two hundred nanograms ofM8G-F(ab')2 was coated to the solid phase and two different 
dilutions of mice immune sera designated as Ml, M2, or M3, as well as pre-immune serum 
were used to inhibit the binding of at biotinylated 25C (at 1/10000 dilution) to M8G-F(ab')2 
(at 2 µg/ml). 
b Data represents the mean value (SEM) of the OD490 obtained from duplicate ELISA 
results. 
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Abstract 
We previously identified pig auto anti-idiotypic antibody (AAb2) specific for the porcine 
reproductive and respiratory syndrome virus (PRRSV) glycoprotein 5 (GP5), and 
characterized AAb2 as an internal image anti-idiotypic antibody (Ab2~). In this study, 
BALB/c mice were immunized with AAb2 and the immune sera (Ab3) were tested for the 
presence of anti-GP5 antibodies and the expression of the idiotype of Ab 1 specific for GP5 
of PRRSV. Mice immunized with AAb2 were able to produce Ahl-like antibody (Id+ Ag+) 
responses, i.e., they recognized the same or a similar epitope as Ab 1 and possessed the Ab 1 
Id, without subsequent exposure to the original antigen. This was demonstrated by following 
results (i) inhibition of the binding of mouse immune serum to AAb2 by PRRSV antigen, (ii) 
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inhibition of binding of mice immune serum to PRRSV antigen by pig antisera, (iii) 
inhibition of AAb2 binding to MAbl-25C by Ab3, and (iv) inhibition of binding of mouse 
immune serum to AAb2 by pig antisera. We conclude that pig auto-anti-idiotypic antibody 
serologically mimics an Ab I-defined GP5 epitope sufficiently to function as a surrogate 
antigen for inducing anti-PRRS virus GP5 responses. 
Introduction 
Porcine reproductive and respiratory syndrome (PRRS), caused by the PRRS virus (PRRSV), 
is a disease of great economic importance for the swine industry worldwide. PRRSV is a 
member of the family Arteriviridae in the order Nidovirales (1). PRRSV is an enveloped 
positive single-stranded RNA virus, which encodes an approximately 4,000-amino-acid large 
replicase polyprotein ( open reading frame [ORF] 1 a and 1 b) and six structural proteins of 
130 to 265 amino acids (ORFs 2 to 7) (2-3). Three of these structural proteins have been 
identified as envelope (25 kDa), matrix (19 kDa), and nucleocapsid (15 kDa) proteins, i.e. 
GP5, M, and N proteins, respectively (4-6). Three additional proteins with molecular masses 
of 29-30 kDa (GP2), 45-50 kDa (GP3), and 31-35 kDa (GP4) have been identified in 
purified Lelystad virus and are presumed to be associated with the viral envelope (5, 7-9). 
Among these viral proteins, GP5 is the major envelope protein and serum neutralizing 
antibody titers were significantly correlated with anti-GP5 titers (10-13). The humoral 
immune response is presumed to play an important role in resistance to reinfection and in 
prevention or reduction of viral spread from animal to animal, since neutralizing antibodies 
have the potential to clear free virus from the circulation (14). 
106 
Anti-PRRSV immunoglobulins in serum after PRRSV infection can be detected within 7 
days of infection. (14-18). Neutralizing antibodies to PRRSV develop between 1 and 2 
months following exposure (15-16, 18-20). Anti-PRRS virus antibodies may persist in blood 
for the lifetime of commercial pigs (14), and PRRSV can persist in some animals despite 
high levels of antiviral antibodies which this is associated with long-term, intermittent 
shedding or seminal excretion of the virus (21-22). 
An idiotope is a single antigenic determinant that is located on the variable regions (V 
domain) of both antibody molecules and receptor molecules ofT and B lymphocytes. 
Idiotopes may be either in the antigen binding site or on the framework regions of the 
variable domain. The sum of the idiotopes on an antibody's V domain determines its 
idiotype. The idiotype (Id) network theory of immune regulation offered by Jeme (23), 
propose that the immune response to a given antigen can be regulated by a series of Id and its 
serological counterpart, an anti-idiotypic antibody (anti-Id or Ab2), has been found useful for 
the production of diagnostic reagents and vaccines. Upon immunization with an idiotypic 
antibody (Ahl), the corresponding anti-Ids are elicited and can be serologically classified 
into four categories (Ab2a, Ab2B, Ab2y and Ab2i::) (24-25). Ab2a recognizes an Id 
associated with the framework region of Abl. Ab2B, an internal image anti-Id Ab2, 
recognizes an Id within the antigen-combining site and bears a structural resemblance to the 
original antigen. The anti-Id mimicry of the original antigen has been experimentally proved 
in many virus systems (26-28). Ab2y, like Ab2B, recognizes an Id within the antigen-
combining site but does not carry the internal image of the original antigen. Ab2E is defines 
as the antibody that binds both Ab 1 and antigen (25). A given idiotypic antibody is under the 
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control of an anti-Id, whereas the anti-Id can be regulated by anti-anti-Id (or Ab3). The 
concept of internal image stems from the possibility of raising Ab3 antibodies that would 
recognize the original Ag. If one takes into account both the specificity and the idiotypic 
characteristics of Ab 1 molecules, four discrete types of Ab3 molecules may be anticipated: 
Id-Ag-, Id+ Ag-, Id-Ag+ and Id+ Ag\ the later being very similar to Abl and termed Abl' (29). 
PRRSV infection poses a challenge to current serodiagnostic and vaccination strategies. 
Because the genetic diversity of field PRRSV isolates is very high, vaccine efficacy against 
heterologous challenge may be limited (30). Also, live PRRSV vaccines have been observed 
to revert to virulence (31-32), and the safer, killed vaccines have so far proved less effective 
(33). A better understanding of the mechanisms that regulate immunity to this virus will aid 
in the development of more effective vaccines. 
We have previously suggested the possible role of auto-anti-idiotypic antibodies (AAb2) in 
immunity to PRRSV infection and characterized pig AAb2 as an internal image anti-
idiotypic antibody (Ab2~) (34-35). In the present study, we describe the characterization of 
an anti-anti-Id, which was produced against a pig AAb2 specific for GP5 of PRRSV and 
determined the structure of Ab3 (Id+ Ag+ or Id+ Ag-). 
Materials and Methods 
PRRSV antigen 
A cell line, MARC-145 was infected with VR-2332 of PRRSV isolate at a multiplicity of 
infection of approximately 5 and the infected cell culture was then incubated and harvested 
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as described by Yoon et al. (16). The total protein concentration of the crude cell culture 
antigen preparation was determined by the method of Lowry et al. (36) using a protein assay 
kit (Pierce, Rockford, IL). 
Antibodies 
MAbl specific for the PRRSV glycoprotein (GP5), designated 25C (IgG1 , 11,), has been 
described elsewhere (34). Purification of AAb2 was performed as described previousely (34-
35). Briefly, normal mouse IgG was covalently coupled to the activated agarose support 
matrix for affinity purification of swine AAb2 specific for GP5 of PRRSV using the 
manufacturer protocol (Bio-Rad Laboratories, Hercules, CA). Swine serums was diluted two-
fold in PBS and passed repeatedly through a normal mouse IgG agarose column until anti-
isotypes and anti-allotypes were completely removed and effluent was collected. The 
unbound serum sample was tested for binding to the solid-phase normal mouse IgG by 
ELISA to ensure that it was free of anti-isotypes and anti-allotypes. The effluent was then 
affinity purified using membrane-bound 25C-F(ab')z fragments. A PVDF membrane (Bio-
Rad Laboratories, Hercules, CA) was first treated with methanol for 5 second, equilibrated in 
the binding buffer (Tris-HCl) and semi-dried between tissue paper. The 25C-F(ab')z at 
1 mg/ml in PBS was loaded on the membrane (5 cm2) for 30 min. The 25C-F(ab')z-coated 
membrane was then incubated in 1 % BSA (w/v) in PBS-T [0.01 M PBS, pH 7.2, containing 
0.01 % (v/v) Tween-20] for another 30 min. After washing three times with PBS-T, the 
membrane was treated with the elution buffer, 0.1 M glycine, pH 5, for 5 min to remove any 
loose-bound F(ab')2 fragments. After washing three times with PBS-T, the membrane was 
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then reacted with pig serum sample diluted 1 :50 in PBS-T for 1 hat room temperature. After 
washing three times with PBS-T, the bound AAb2 were eluted with the elution buffer. This 
elution buffer at pH 5 was chosen because at lower pH (pH 2-3), some coated F(ab')2 
fragments were also eluted out along with the AAb2. The pH of AAb2 solution was 
immediately adjusted to pH 7 with 3 M Tris-base solution. After the elution with the elution 
buffer, the bound AAb2 was completely eluted out, which was evidenced by the lack of 
reaction of the membrane with HRP-goat anti-swine IgG (data not shown). IgG concentration 
was estimated at 280 nm using a spectrophotometer (SmartSpec 3000, Bio-Rad Laboratories, 
Hercules CA) with the extinction coefficient of 1.35. The purity of antibodies was confirmed 
by SDS-PAGE. 
Enzymatic digestion of antibodies 
To prepare F(ab')z, the purified 25C-lgG and AAb2-IgG were digested using pepsin (Sigma, 
St. Louis, MO) as described previously (34). A papain digestion was performed to prepare 
AAb2-Fab based on method described elsewhere (37). The purity ofF(ab')2 and Fab were 
confirmed using SDS-PAGE and ELISA. 
Pig sera 
Pig antisera samples were collected from a group of pigs experimentally infected with 
PRRSV. The presence of anti-PRRSV antibodies was confirmed by IF A and HerdCheck 
ELISA as described in our previous studies (34-35). 
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Production of anti-anti-idiotypic antibody (Ab3) specific for GP5 of PRRSV 
For induction of Ab3, AAb2 was used in the form ofFab coupled to KLH (Fab-KLH). 
Three, six week-old female BALB/c mice were immunized intraperitoneally (IP) on day 0, 
with 50 µg of AAb2-Fab-KLH (50 µgin 100 µl of PBS) emulsified 1 :1 in Freund's complete 
adjuvant (Total vol.= 0.2 ml). Two booster injections were given on days 14 and 28 each 
with 50 µg of the same anti-idiotype preparation in Freund's incomplete adjuvant. Two 
weeks after the final injection, mice were bled and the serum samples tested for the presence 
of anti-anti idiotypic antibody (Ab3) in serum by an ELISA with AAb2-Fab on solid-phase. 
The antibody end point titre (EPT) was expressed as the highest serum dilution that gave the 
absorbance at 490 nm 3-fold higher than that for pre-immune serum. 
Detection of anti-anti-Id antibody (Ab3) 
The presence of anti-anti-Id antibodies (Ab3) in the sera from mice immunized with AAb2 
was tested by an indirect ELISA. The solid phase was prepared by coating the wells of 
ELISA plates (Nalge Nunc International, Roskilde, Denmark) with AAb2-F(ab')2 or normal 
pig F(ab')2 fragments at 2 µg/ml (100 µ1/well) in PBS (10 mM, pH 7.2) at 4 °C, overnight. 
After washing the plate with PBS containing 0.05 % of Tween-20 (PBS-T, v/v), individual 
mouse serum were diluted in 5% normal pig serum (NPS) in PBS-T and added to the wells 
(100 µ1/well) in duplicates and incubated for 45 min at room temperature. The wells were 
washed again three times with PBS-T and the presence of Ab3 that bound to the solid-phase 
AAb2-F(ab')2 was detected by the addition ofHRP-goat anti-mouse IgG (Jackson 
ImmunoResearch, West Grove, PA) diluted 2000-fold in PBS-T (100 µ1/well) for 45 min at 
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room temperature. After final washing with PBS-T, the substrate o-phenylene diamine (OPD, 
100 µ1/well) was added to all wells to develop the colorimetric reaction at the room 
temperature for 15 min. The reaction was then stopped by adding 3 M H2SO4 in each well 
(100 µ1/well) and read at OD 490 nm on an automatic ELISA plate reader (Universal 
Microplate Reader, EL800, Bio-Tek Instrument, Inc., Winooski, VT). 
Competitive ELISAs 
To determine whether PRRSV antigen could inhibit AAb2 binding to Ab3, a C-ELISA was 
performed by coating of AAb2-F(ab')2 (0.2 µg/well) onto the ELISA plate. The mouse serum 
(M 1 ), at the final concentration of 1: 1000) was used in the liquid-phase with or without 
mixing with individual inhibitors including PRRSV antigen and MARK 145 cell line (as a 
control) at 100 and 10 µg/ml. After washing the plates 3 times with PBS-T, HRP-goat anti-
mouse IgG diluted 2000-fold in PBS-T (100 µ1/well) for 45 min at room temperature was 
added. After final washing with PBS-T for three times, substrate solution, OPD (100 µ1/well) 
was added to all wells to develop the colorimetric reaction at the room temperature for 
15 min. The reaction was stopped by adding 3 M H2SO4 in each well (100 µ1/well) and the 
OD was read at 490 nm on an automatic ELISA plate reader. The percent inhibition was 
calculated by the following formula: 
% INHIBITION= [1 - (OD490 with competitor - background OD490) / (OD490 without 
competitor - background OD490)] x 100. 
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To further confirm the specificity of Ab3 for PRRSV, the ability of pig antisera (Abl) to 
inhibit Ab3 from binding to the solid-phase PRRSV antigen was tested by competitive 
ELISA. For this purpose 96-well microtitre plates were coated with PRRSV Ag 
(100 µ1/well) , 2 µg/ml in PBS (0.0lM, pH 7.2) and incubated over night at 4°C. The mouse 
serum immunized with AAb2 (1/10000 dilution) was used in the liquid-phase with or without 
mixing with individual pig antisera along with pre-immune serum at 1/10 and 1/100 dilution. 
100 µ1 of the mixture were added to the wells and kept for 1 hat room temperature followed 
by washing three times with PBS-T. The conjugate used in the C-ELISA was HRP-goat anti-
mouse IgG at 1 :2000 dilution in PBS-T (100 µ1/well) . The addition of the substrate and 
quantitation of the calorimetric reaction was performed as described above. The percent of 
inhibition was calculated by the same formula. 
Furthermore, a C-ELISA was performed to determine whether Ab3 could inhibit AAb2 
binding to MAbl . For this purpose, the solid phase was prepared by coating the wells of 
plate with 25C-F(ab')2 (2 µg/ml in PBS). The AAb2 (100 µg/ml dilution) was used in the 
liquid-phase with or without mixing with individual mice sera immunized with AAb2 (Ab3), 
at 1/100. 100 µl of the mixture were added to the wells and kept for 1 hat room temperature 
followed by washing three times with PBS-T. The conjugate used in the C-ELISA was HRP-
goat anti-swine IgG at 1 :2000 dilution in PBS-T ( 100 µ1/well). The rest of assay was 
performed as the same described previously and the degree of inhibition ofld-anti-Id 
interaction was calculated by the formula described above. 
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To determine whether Ab3 express an Id of Abl, the ability of pig antisera (Abl) to inhibit 
mouse immune serum (Ab3) from binding to the solid-phase AAb2 were evaluated by an 
inhibition ELISA. Similarly as described above, AAb2-F(ab')2 (2 µg/ml in PBS) was 
absorbed to wells of an ELISA plate. After washing the plate 3 times with PBS-T, serum 
from the mouse immunized with AAb2 ( at final dilution of 1: 1000 in PBS-T) was mixed 
with various pig sera (1: 10 and 1: 100 dilutions in PBS-T) and 100 µl of the mixture was 
added to the wells and incubated for 45 min at room temperature. The wells were washed 
three times with PBS-T and the inhibition of Ab3 to the AAb2 was detected by the addition 
ofHRP-goat anti-mouse IgG diluted 2000-fold in PBS-T (100 µI/well). The plates were 
incubated for another 45 min at room temperature. The percent inhibition was calculated by 
the formula described above. 
Results 
Induction of anti-anti-Id antibody 
Immunization with swine AAb2 in a xenogenic system was done and the induced anti-anti-Id 
antisera (Ab3) were analyzed with an indirect ELISA. Murine sera were diluted in PBS-T 
containing 5% NPS and tested for binding to the solid-phase AAb2-F(ab')2 or normal pig 
IgG. Fig.I shows the binding activities of three mouse serum immunized with anti-Id 
antibody (AAb2). Under assay conditions employed, the absorbance values at 490 nm for 
binding of Ml, M2 and M3 immune sera at 1/10000 dilution to the solid-phase AAb2 were 
2.42, 2.02 and 2.3, respectively, which were much greater than those for binding of the same 
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antisera to normal pig F(ab')2 (Fig. l). Pre-immune sera from all immunized mice showed 
negligible immunoreaction with AAb2 or normal pig lgG (data not shown). 
Ab3 antibodies recognize the Ahl-specific epitope ofGP5 
To determine whether Ab3 antibodies possessed Abl-like properties with specificity for the 
PRRSV antigen, two competitive ELISA were performed. First a C-ELISA was used to 
determine whether PRRSV antigen could inhibit Ab3 binding to AAb2. As shown in Fig. 2, 
PRRSV antigen compare to MARK 145 cell line, significantly (P<0.05) inhibited (73 and 53 
% at 1000 and 100 µg/ml, respectively) Ab3 binding to AAb2. 
To further confirm the specificity of Ab3 for PRRSV antigen, the immune sera were tested 
additionally by the second immunoassay. AC-ELISA was employed for the ability of pig 
antisera to inhibit immune serum from binding to the solid-phase PRRSV antigen. As shown 
in Table 1, the pig antisera significantly (P<0.05) inhibited the Ab3-PRRSV antigen 
interaction. The highest and lowest percentages of inhibition were 84 and 31.4 ( at a dilution 
of 1: 10), respectively. Pig negative serum did not show any inhibitory effects. These results 
demonstrated that AAb2 did induce the production of anti-GP5 antibodies. 
Ab3 antibodies possess the Id of Ab] 
To determine whether Ab3s express an Id of Ab 1, the immune sera were evaluated for their 
ability to inhibit AAb2 from binding to the solid-phase 25C by a C-ELISA. Figure 3 shows 
the percent of inhibition ofld-anti-Id reaction by mice immune sera (Ml, M2, and M3) were 
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66, 74, and 68 %, respectively. Negligible inhibitory effects were found with the normal 
mouse serum (8.5 %). 
Common anti-Id 
To examine whether a common idiotope was present at a significant level in the Ab3 anti 
GP5 antibodies, the ability of pig antisera (Abl) to inhibit mouse immune serum (Ab3) from 
binding to the solid-phase AAb2 by an inhibition ELISA. Table 2 shows that pig antisera at 
1: 10 dilution, significantly (P<0.05) inhibit binding of Ab3 to AAb2, while pre-immune pig 
serum did not affect binding of Ab3 antibodies to AAb2. 
Discussion 
We have previously identified pig auto anti-idiotypic antibody (AAb2) specific for the 
porcine reproductive and respiratory syndrome virus (PRRSV) glycoprotein GP5, and 
showed that AAb2 possessed the properties of an internal image anti-Id (Ab2P) (34-35). 
Based on Jerne's idiotype network theory (23) and confirmed by Bona and Kohler (38) anti-
idiotypic antibodies can be classified into four categories: Ab2a, Ab2P, Ab2y and Ab2E. 
These individual anti-idiotypic antibodies have been produced against various antigens and 
used to modulate the specific immune response against the original antigens (24, 38). In 
particular, an internal image of anti-idiotype (Ab2P) has been studied to modulate the 
specific antibody responses against bluetongue virus VP2 (39) and VP7 (40), HBV (41), and 
HIV (28). In this study, BALB/c mice were immunized with AAb2 and the immune sera 
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(Ab3) were tested for the presence of anti-GP5 antibodies and the expression of the Id of Abl 
specific for GP5 of PRRSV. 
One prevailing concept in immunology developed from the idiotypic network theory (23) is 
that the immune response to a given antigen can be regulated by a series ofld-anti-Id 
interactions. The expression of a given Id is under the control of an anti-Id and the anti-Id can 
also be regulated by an anti-anti-Id. This complex set of interactions operates via a feedback 
mechanism to either enhance or suppress the immune response (i.e. formation of antibodies 
with a particular idiotype). Our previous investigations on the immune response to PRRSV 
indicate the existence of the Id network (34-35). However, the role(s) of the Id-anti-Id 
networks in controlling the immune response to PRRSV is (are) not completely known at this 
time. 
The results of the present study demonstrated that immunization of mice with AAb2 led to 
the generation of an anti-GP5 antibody response with epitope specificity similar to that of 
Abl, as the interaction between anti-anti-Id and AAb2 was inhibited by PRRSV antigen 
(Fig.2), and the interaction between Ab3 and PRRSV antigen was inhibited by pig antisera to 
PRRSV antigen (Table 1 ). The finding that the binding of AAb2 to MAb 1 (25C) was 
inhibited with Ab3 (Fig. 3), and pig antisera (Ab 1) inhibited interaction between Ab3 and 
anti-Id (Table 2), show that auto-anti-Id produced the anti-anti-Id which recognized the 
idiotypes that were shared by mouse and pig anti-PRRSV antibodies. Because the antibodies 
to GP5 in the swine sera are of polyclonal origin and, therefore, are capable ofrecognizing 
any of the determinants of PRRSV e.g. Mand N proteins and or other glycoproteins (GP2, 
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Gp3, GP4), it is evident that only that fraction of the entire repertoire of antibodies which is 
(i) directed to GP5 of PRRSV and (ii) possesses the Id which is the same or similar to that of 
25C, has the capacity to inhibit the Id-anti-Id interaction. Therefore, it was not surprising to 
find that the swine sera were not able to completely inhibit the Ab3-AAb2 interaction. 
The relationship between Ab 1 and Ab 1' antibodies has been explored in a number of 
different antigenic systems, and with either monoclonal or polyclonal anti-Id reagents (42). 
One result obtained consistently is that among Ab3 antibodies are some antibodies that do 
indeed closely resemble the Ab 1 in that they possess the same idiotopes, bind to the same 
antigen and derive from similar variable (V) genes. However, whilst the resemblance 
between Abl' and Abl can be very close, many permutations ofresults have been seen. For 
example, binding of Ab3 to the antigen may not occur even although the same V -gene 
segments are selected, e.g. where the selection by anti-Id is directed towards the V segment 
rather than D and J idiotopes; or the affinity of Ab 1' antibodies for antigen may be lower than 
that of the Ab 1, corresponding to differences in the complementarity determining region 
(CDR), particularly H3 sequences; or the Ab3 may bind a similar antigen, yet diverge 
considerably from the Ab 1 in V genes and CD Rs. Thus, depending perhaps on the nature of 
the Ab2 reagent, an Ab3 population can be more or less heterogeneous and include 
molecules with a range of fidelities to the Ab 1. 
According to Goldbaum et al. ( 43), there are two major possibilities for the induction of anti-
anti-Id (Ab3) that resemble Abl. One is that a suitably selected anti-Id will mimic the antigen 
so closely as to produce the equivalent of an antibody response to the original antigen. A 
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second possibility is that the anti-Id is specific for the Id and will thus stimulate lymphocytes 
displaying anti-anti-Id immunoglobulins that should be identical or essentially identical to 
the Ahl. By immunochemical criteria it is difficult to discriminate between Ab2~ and Ab2y. 
To sort out both types of Ab2 a functional demonstration should be observed. Since Ab2~ 
express an idiotype that mimics the antigen, it might have the capacity to elicit antibodies 
specific for the antigen in the same or different species. The production and characterization 
of Ab3 confirms our findings that immunization with anti-GP 25C to modulate the idiotypic 
cascade by eliciting Ab2~ antibodies that, in tum, have the capacity to stimulate specific B 
cell clones to secrete Ab3 antibodies. The mouse serum containing Ab3 recognized 
specifically PRRSV antigen in EIA assays, showing a typical saturation pattern. Moreover, 
Ab3 recognized a common Id on the pig antisera against GP5. Investigations using a murine 
model system are in progress to determine whether the swine AAb2 can modulate the 
immune response to PRRSV. 
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FIGURE 1. Binding curves of mice immune sera to AAb2 and normal pig F(ab')z. Immune 
sera from mouse immunized with AAb2 were diluted in PBS-T containing 5% NPS and 
tested for binding to the solid phase AAb2 F(ab')z (top) and normal pig F(ab')2 (below) by an 
indirect ELISA. Each data point represents the mean value (SEM) of the OD490 obtained 
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FIGURE 2. Inhibition of the binding of mouse immune serum to AAb2 F(ab')2 fragments. 
PRRSV antigen along with MARK 145 cell control antigen at different concentrations, were 
used to inhibit binding ofmurine serum samples obtained from mice that were immunized 
with AAb2 immunized to the solid-phase AAb2-F(ab')2. Each point represents the mean 
(SEM) of the percent inhibition obtained from duplicate ELISA results. 
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Table 1. Inhibition of binding of mouse immune serum (Ab3) to PRRSV antigen a 
by pig antisera. 
Pig no. Serum Dilution % Inhibition 
Pl 1/10 84 
1/100 34 
P2 1/10 31.4 
1/100 28.5 
P3 1/10 41.3 
1/100 26.4 
P4 1/10 39 
1/100 20.5 
P5 1/10 53 
1/100 20.4 
P6 1/10 87 
1/100 31.6 
P7 1/10 32 
1/100 26.4 
PS 1/10 33.5 
1/100 20.9 
P9 1/10 35 
1/100 19.9 
Pl0 1/10 57.5 
1/100 41.8 
Pre-immune 1/10 6.5 
1/100 1.1 
a Two hundred nano grams of PRRSV antigen was coated to the solid phase and two different 
dilutions of individual swine antisera were used to inhibit the binding of mouse immune 
serum at 1/1000 dilution to antigen. 
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FGURE 3. Inhibition of AAb2 binding to 25C by Ab3s. 
a Two hundred nanograms of25C-F(ab')2 was coated to the solid phase and murine immune 
sera with AAb2-Fab designated as Ml, M2, and M3 diluted in 5% norm! pig serum and 
normal mouse serum (M4), were used to inhibit the binding of AAb2 (100 µg/ml) to 25C-
F(ab')2 (2 µg/ml). 
b Data represent the mean (SEM) of the percent inhibition obtained from duplicate ELISA 
results. 
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Table 2. Inhibition of binding of mouse immune serum (Ab3) to AAb2a 
by pig antisera 
Pig no. Serum Dilution % Inhibition 
Pl 1/10 64 
1/100 33.6 
P2 1/10 30.5 
1/100 16.2 
P3 1/10 34 
1/100 6 
P4 1/10 31 
1/100 12.7 
PS 1/10 39.5 
1/100 24.5 
P6 1/10 60 
1/100 26.4 
P7 1/10 30 
1/100 12.5 
PS 1/10 36 
1/100 9.7 
P9 1/10 36 
1/100 22 
Pl0 1/10 43 
1/100 20.5 
Pre-immune 1/10 4.8 
1/100 3.5 
a Two hundred nanograms of AAb2-F(ab')2 was coated to the solid phase and two different 
dilutions of individual swine antisera were used to inhibit the binding of mouse immune 
serum at 1/1000 dilution to AAb2. 
b Each number represents the mean (SEM) of the percent inhibition obtained from duplicate 
ELISA results. 
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CHAPTER 4. GENERAL CONCLUSION 
According to the idiotypic network hypothesis proposed by J erne in 197 4, different antigenic 
determinants within variable domains of immunoglobulins can be recognized and can elicit 
an immune response in the same individual. These antigenic determinants are known 
collectively as idiotypes (Ids). According to this original network hypothesis, the Id-anti-Id 
interactions regulate the immune response of a host to a given antigen. The network 
hypothesis predicts that within the immune network the universe of external antigens is 
mimicked by idiotypes expressed by antibodies and T cell receptors. According to the 
network concept, immunization with a given Ag will generate the production of antibodies 
against this Ag termed Ab 1. This Ab 1 can generate a series of anti-Id antibodies against Ab 1 
termed Ab2. Some of these Ab2 molecules can effectively mimic the three-dimensional 
structures of external antigens. These particular anti-Ids called Ab2~, which fit into the 
paratopes of Ab 1, can induce specific immune responses similar to responses induced by 
nominal Ag. Immunization with Ab2~ can lead to the generation of anti-anti-Id antibodies 
(Ab3) that may recognize the corresponding original Ag identified by the Abl. Because of 
this Ab 1-like reactivity, the Ab3 is also called Ab 1' to indicate that it might differ in its other 
idiotopes from Ab 1. 
In the first study, we described the generation and characterization of a monoclonal anti-Id, 
designated as MSG, directed to an Id on monoclonal antibody, 25C. 25C recognized an 
epitope referred to as glycoprotein 5 (GP5) on the PRRSV. Based on the following results we 
concluded that anti-Id MSG recognized an Id either within or near the antigen combining 
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sites ofMAbl-25C and possessed common Id to antibodies that are formed to GP5 in 
unrelated species: (i) Id-anti-Id interaction could be inhibited by PRRSV antigen, and (ii) 
Anti-Id inhibited the interaction between MAbl and PRRSV antigen. According to the 
classification of anti-idiotypic antibodies, the anti-Id MSG has the characteristics of an 
internal image anti-Id. 
To further study ofld network in PRRSV infection, monoclonal anti-Id (MSG) was used to 
induce an anti-anti-idiotypic antibodies (Ab3) response in murine model. Based on the 
following results we concluded that monoclonal anti-Id produced the anti-anti-Id that 
possessed Ab I-like (Ab l ') properties with specificity for the PRRSV antigen in murine 
model: (i) the binding of anti-anti-Id to anti-Id was inhibited by PRRSV antigen, (ii) anti-
anti-Id antibody competed with Abl binding to PRRSV antigen, and (iii) Id-Anti-Id 
interaction was inhibited by Ab3. Investigations using a murine model system are in progress 
to determine whether the anti-Id MSG can modulate the immune response to PRRSV. 
To further investigation of Id-anti-Id network in PRRSV infection, the second study was 
conducted using swine auto anti-idiotypic antibody (AAb2). We have previously identified 
pig auto anti-idiotypic antibody specific for GP5 of PRRSV, and characterized AAb2 as an 
internal image anti-Id (Ab2B). In this study, BALB/c mice were immunized with AAb2 and 
the immune sera (Ab3) were tested for the presence of anti-GP5 antibodies and the 
expression of the Id of Abl specific for GP5 of PRRSV. 
We concluded that immunization of mice with AAb2 led to the generation of an anti-GP5 
antibody response with epitope specificity similar to that of Ab 1 (Ab I-like or Ab l' response) 
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in murine model for the following reasons: (i) Id-anti-Id interaction was inhibited by Ab3, 
(ii) the binding of anti-anti-Id to AAb2 was inhibited with PRRSV antigen, (iii) pig antisera 
to PRRSV inhibited the interaction between Ab3 and PRRSV antigen, and (iv) Ab3-AAb2 
interaction was inhibited by pig antisera. The finding that the binding of AAb2 to MAb 1 
(25C) was inhibited by Ab3, and pig antisera (Ahl) inhibited interaction between Ab3 and 
anti-Id, show that auto-anti-Id produced the anti-anti-Id which recognized the idiotypes that 
were shared by mouse and pig anti-PRRSV antibodies. 
Further studies on anti-PRRSV antibody and anti-idiotypic antibody responses and their 
relationship with cellular immune responses would be necessary to understand the immune 
responses against PRRSV and to develop a strategy to control PRRSV antigen. 
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